Medical devices

“For example, by taking over the operation of certain portions of our clients’ businesses, including functions and systems that are critical to the core businesses of our clients, by contributing to the design, development, manufacturing and/or engineering of client products, or by providing various operational technology, digital manufacturing and robotics or other industrial automation equipment solutions, and advisory, management and engineering services for infrastructure projects, we may be exposed to additional and evolving operational, regulatory, reputational or other risks specific to these areas, including risks related to data security, product liability, health and safety, hazardous materials and other environmental risks.”

Annual report 2025A · The company itself

“Bactiguard är väl positionerat för att dra nytta av den växande globala marknaden för medicintekniska produkter, där våra fokusområden totalt beräknas ha en marknadsstorlek som överstiger 70 miljarder USD år 2030.”

Annual report 2024A · The company itself

“I mars 2025 offentliggjorde Bactiguard sina uppdaterade strategiska och finansiella mål:  att ha minst tio applikationsområden i antingen exklusiva partnerskap eller licenspartnerskap vid utgången av 2030,  att leverera en omsättning på minst 600 MSEK vid utgången av 2030, och  att leverera en EBITDA på minst 200 MSEK vid utgången av 2030.”

Annual report 2024A · The company itself

“Vi fasade ut BIP-portföljen med egna medicintekniska produkter och fördjupade samarbetet med vår licenspartner BD (Becton, Dickinson & Company) genom att stötta den fortsatta överföringen av Bactiguards marknader för BIP Foleykatetrar till BD.”

Annual report 2024A · The company itself

“Bactiguard är ett globalt medtech-bolag som utvecklar säker och biokompatibel teknologi som förebygger infektioner relaterade till medicintekniska produkter. Den unika teknologin är baserad på ett ultratunt ädelmetallytskikt som förhindrar bakterier från att fästa och bilda biofilm på medicintekniska produkter. Bolaget fokuserar på fem strategiska terapiområden i vilka förekomsten av infektioner medför ett högt medicinskt behov av infektionsprevention. Dessa områden inkluderar ortopedi, kardiologi, neurologi, urologi och vaskulär åtkomst.”

Annual report 2024A · The company itself

“Bolaget har också en portfölj med produkter för sårhantering.”

Annual report 2024A · The company itself

“Bactiguards primära varumärke för sårhantering är Hydrocyn aqua, en innovativ produktlinje som främjar sårläkning och förebygger infektioner.”

Annual report 2024A · The company itself

“I sortimentet ingår även ett omfattande urval av kirurgiska suturer, inklusive specialvarianter för hjärtoch ögonkirurgi.”

Annual report 2024A · The company itself

“New or unintended uses of our products may also raise quality or safety issues. In addition, our customers’ use of third parties to service or repair our products has caused, and may in the future cause, quality or safety issues, including due to such third parties’ lack of knowledge of or training on our products. A quality or safety issue has resulted in, and may in the future result in one or more of the following: product recalls (either voluntary or required by FDA or similar governmental authorities in other countries); adverse regulatory site inspections and/or inspectional classifications; warning letters; other regulatory actions; import bans; seizures; injunctions; monetary sanctions; civil or criminal sanctions (which may include corporate integrity agreements); costly litigation; refusal of a government to grant clearances, approvals, and/or licenses; restrictions on operations; or withdrawal of existing approvals and licenses.”

Annual report 2025A · The company itself

“Novum IQ Large Volume Pump (Novum LVP) Beginning in April 2025, we initiated a voluntary correction for the Novum LVP due to the potential for under-infusion when the pump is in "standby mode" for an extended period of time. Beginning in July 2025, we initiated voluntary corrections for the Novum LVP due to the potential for under-infusion when the pump is directed to deliver a bolus infusion or significantly increase the rate of infusion after it has been running at a lower infusion rate and the potential for over- and under-infusion related to set misloading, as well as certain software anomalies.”

Annual report 2025A · The company itself

“Infusion Therapies & Technologies net sales were flat for the year ended December 31, 2025, as compared to the prior year period. Sales performance in 2025 was primarily driven by lower sales as a result of the ship and installation hold on Novum LVP and lower demand in our IV Solutions business in the U.S. as customers continued 36 fluid conservation practices embedded with clinical practice changes.”

Annual report 2025A · The company itself

“Our success also depends on our ability to maintain and routinely improve product quality and our quality management program. Quality management plays an essential role in helping to meet customer requirements, prevent defects, improve our products and services, and assure the safety and efficacy of our products.”

Annual report 2025A · The company itself

“EXECUTIVE OVERVIEW Description of the Company, Recent Strategic Actions and Business Segments Baxter International Inc. is a global medical technology with approximately 37,500 employees worldwide who are engaged in the development, manufacture and sale of a broad range of products, digital health solutions and therapies used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices and patients at home under physician supervision.”

Annual report 2025A · The company itself

“NET SALES BY SEGMENT Medical Products & Therapies Our Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products.”

Annual report 2025A · The company itself

“Pharmaceuticals Our Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthetics and drug compounding services.”

Annual report 2025A · The company itself

“Medical Device Regulations A number of our products are classified as medical devices and are subject to restrictions under domestic and foreign laws, rules, regulations, self-regulatory codes and orders, including but not limited to the U.S. Food, Drug and Cosmetic Act (the “FDCA”). The FDCA requires these products, when sold in the U.S., to be safe and effective for their intended uses and to comply with the regulations administered by the U.S. Food and Drug Administration (“FDA”).”

Annual report unknown yearA · The company itself

“As a medical device manufacturer, our manufacturing facilities are subject to inspection on a routine basis by the FDA. We are required to adhere to the Current Good Manufacturing Practices (“cGMP”) requirements, as set forth in the Quality Systems Regulation (“QSR”), which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all phases of the design and manufacturing process.”

Annual report unknown yearA · The company itself

“Labeling and promotional activities are subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade Commission. Medical devices approved or cleared by the FDA may not be promoted for unapproved or uncleared uses, otherwise known as “off-label” promotion. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.”

Annual report unknown yearA · The company itself

“In the European Union (“EU”), our products are subject to the medical device laws of the various member states, which are currently based on a Directive of the European Commission. Additionally, the EU has adopted the In Vitro Diagnostic Regulation (the “EU IVDR”), which imposes stricter requirements for the marketing and sale of in vitro diagnostic medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance.”

Annual report unknown yearA · The company itself

“Consequently, we must comply with state licensing regulations applicable to laboratories regulated under CLIA, governing laboratory practices and procedures.”

Annual report unknown yearA · The company itself

“Other Healthcare Laws Some of the products and services we sell, predominantly in our Diagnostics and Spatial Biology segment, are subject to various health care related laws regulating fraud and abuse, research and development, pricing and sales and marketing practices, and the privacy and security of health information, including, among others: ● U.S. federal regulations regarding quality and cost by the U.S. Department of Health and Human Services (“HHS”), including the Centers for Medicare & Medicaid Services (“CMS”), as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of healthcare goods and services, including laws and regulations related to kickbacks, false claims, self-referrals and healthcare fraud.”

Annual report unknown yearA · The company itself

“●The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which prohibits knowingly and willfully (1) executing, or attempting to execute, a scheme to defraud any health care benefit program, including private payors, or (2) falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, 11 Table of Contents items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, also restricts the use and disclosure of patient identifiable health information, mandates the adoption of standards relating to the privacy and security of patient identifiable health information and requires the reporting of certain security breaches with respect to such information.”

Annual report unknown yearA · The company itself

“●The Open Payments Act requires manufacturers of medical devices covered under Medicare to, in certain circumstances, record payments and other transfers of value to a broad range of healthcare providers and teaching hospitals and to report this data as well as ownership and investment interests held by the physicians described above and their immediate family members to HHS for subsequent public disclosure, as well as similar reporting requirements in some states and in other countries.”

Annual report unknown yearA · The company itself

“In the first quarter of fiscal 2024, we closed on the acquisition of Lunaphore, a leading developer of fully automated spatial biology solutions using precision microfluidic technology capable of revealing hyperplex proteomic and transcriptomic biomarkers in tumors and other tissues at single-cell and subcellular resolution.”

Annual report unknown yearA · The company itself

“The majority of Bio-Techne Diagnostic division’s sales are through OEM agreements, but we sell some of our diagnostic reagent products directly to customers and, in Europe and Asia, also through distributors.”

Annual report unknown yearA · The company itself

“We intend to build on Bio-Techne’s past accomplishments, high product quality reputation and sound financial position by executing strategies that position us to serve as the standard for biological content in the research market, and to leverage that leadership position to enter the diagnostics and other adjacent markets.”

Annual report unknown yearA · The company itself

“Our Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications.”

Annual report unknown yearA · The company itself

“The Analytical Solutions division includes manual and automated protein analysis instruments and immunoassays that are used in quantifying proteins in a variety of biological fluids. Products in this division include traditional manual plate-based immunoassays, fully automated multiplex immunoassays on various instrument platforms, and automated western blotting and isoelectric focusing analysis of complex protein samples.”

Annual report unknown yearA · The company itself

“Diagnostics and Spatial Biology Segment Products The Spatial Biology division products sold under the Advanced Cell Diagnostics, or ACD, brand, are novel in-situ hybridization (ISH) assays for transcriptome, DNA copy, and structural variation analysis within intact cells, providing highly sensitive and specific spatial information at single cell resolution. Since these products preserve spatial context, they are particularly useful for complex tissue profiling.”

Annual report unknown yearA · The company itself

“Lunaphore’s COMET instrument automates ACD’s RNAscope assays and utilizes antibodies to enable simultaneous hyperplex detection of protein and RNA biomarkers on the same slide at single-cell resolution.”

Annual report unknown yearA · The company itself

“The Bio-Techne Diagnostic division consists of regulated products traditionally used as calibrators and controls in the clinical setting. Also included are instrument and process control products for hematology, blood chemistry, blood gases, coagulation controls and reagents used in various diagnostic applications.”

Annual report unknown yearA · The company itself

“Most of these products are sold on an Original Equipment Manufacturer (OEM) basis to instrument manufacturers, with most products being FDA-cleared.”

Annual report unknown yearA · The company itself

“In addition to being useful research tools, our DNA and RNA in situ hybridization (ISH) assays have diagnostics applications, and several are cleared or currently under review by the FDA in partnership with diagnostics instrument manufacturers and pharmaceutical companies.”

Annual report unknown yearA · The company itself

“The Asuragen-branded products are sold primarily to laboratories for use in lab-developed tests or in kit form as regulated diagnostic tests.”

Annual report unknown yearA · The company itself

“The manufacture, distribution and marketing of many of our products and services, including medical devices and pharma services, are subject to extensive ongoing regulation by the FDA, the DEA, and other equivalent local, state, federal and non-U.S. regulatory authorities.”

Annual report unknown yearA · The company itself

“Certain of our products are medical devices, diagnostics tests and other products that are subject to regulation by the U.S. FDA or state CLIA regulations, by other federal and state governmental agencies, by comparable agencies of other countries and regions and by regulations governing hazardous materials and drugs-of abuse, or the manufacture and sale of products containing any such materials.”

Annual report unknown yearA · The company itself

“This segment also sells to diagnostic/companion diagnostic and therapeutic customers, including those engaged in the development of cell- and gene-based therapies.”

Annual report unknown yearA · The company itself

“In addition, the medical device markets in which we participate are characterized by extensive research and development and rapid technological change. Developments by other companies of products and/or services, processes or technologies, including low-cost alternatives, may make our products or proposed products obsolete or less competitive and may negatively impact our net sales.”

Annual report 2025A · The company itself

“Research and Development Our investment in research and development is critical to driving our future growth. Our investment in research and development supports internal research and development programs, regulatory design and clinical science, and other programs obtained through our strategic acquisitions and alliances, as well as engineering efforts that incorporate customer feedback into continuous improvement efforts for currently marketed and next-generation products.”

Annual report 2025A · The company itself

“In the second quarter of 2025, we completed our acquisition of the remaining shares of Bolt Medical, Inc. (Bolt Medical), the developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease.”

Annual report 2025A · The company itself

“Product Offerings Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.”

Annual report 2025A · The company itself

“MedSurg Endoscopy Our Endoscopy business unit develops and manufactures minimally invasive devices for diagnosing and treating gastrointestinal and pancreaticobiliary conditions and for supporting weight loss in patients with obesity.”

Annual report 2025A · The company itself

“Urology Our Urology business unit develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and male incontinence, over active bladder and pelvic floor disorders.”

Annual report 2025A · The company itself

“Neuromodulation Our Neuromodulation business unit develops and manufactures devices to treat various neurological movement disorders and manage chronic pain.”

Annual report 2025A · The company itself

“Cardiovascular Interventional Cardiology and Vascular Therapies (ICVT) Our Interventional Cardiology and Vascular Therapies business unit develops and manufactures technologies to diagnose and treat complex coronary, peripheral and venous diseases, including calcific and obstructive arterial disease, thromboembolic conditions and venous insufficiency. Our portfolio includes intravascular imaging and multi-modality guidance systems that enhance procedural visualization and decision-making (OptiCross™ IVUS Imaging Catheters and AVVIGO™+ Multi-Modality Guidance System), vessel preparation and plaque modification technologies for heavily calcified and resistant coronary lesions (ROTAPRO™ Rotational Atherectomy Systems and WOLVERINE™ Coronary Cutting Balloon), coronary drug-eluting and drug-coated therapies designed to treat coronary arterial disease and in-stent restenosis (SYNERGY™ Everolimus-Eluting Stent Systems and AGENT™ Drug-Coated Balloon) and peripheral vascular therapies for the treatment of peripheral artery disease (Eluvia™ Drug-Eluting Vascular Stent Systems and Ranger™ Drug-Coated Balloons).”

Annual report 2025A · The company itself

“Watchman Our WATCHMAN™ Left Atrial Appendage Closure (LAAC) Devices are designed to close the left atrial appendage in patients with non-valvular atrial fibrillation (AF) who are at risk for ischemic stroke and eligible for anticoagulation therapy. WATCHMAN™ is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally.”

Annual report 2025A · The company itself

“Electrophysiology Our Electrophysiology business unit develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart, including a broad portfolio of therapeutic and diagnostic catheters and a variety of equipment used in the Electrophysiology lab.”

Annual report 2025A · The company itself

“Cardiac Rhythm Management Our Cardiac Rhythm Management (CRM) business unit develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. Our product offerings include implantable cardioverter defibrillators (ICD) (RESONATE™) and implantable cardiac resynchronization therapy defibrillators (CRT-D) (HeartLogic™ Heart Failure (HF) Diagnostic and SmartCRT™ Technology), subcutaneous implantable cardiac defibrillators (S-ICD) (EMBLEM™ MRI S-ICD System), which provide physicians the ability to treat patients who are at risk for sudden cardiac arrest without touching the heart, pacemakers and implantable cardiac resynchronization therapy pacemakers (CRT-P) (ACCOLADE™), remote patient management systems (LATITUDE™) and cardiac monitoring systems (BodyGuardian™ Remote Cardiac Monitoring Systems provide a full range of mobile health solutions and remote monitoring services), and our LUX-Dx II+™ Insertable Cardiac Monitor System, a long-term diagnostic device implanted in patients to detect arrhythmias associated with conditions such as AF, cryptogenic stroke and syncope.”

Annual report 2025A · The company itself

“Interventional Oncology and Embolization Our Interventional Oncology and Embolization business unit develops and manufactures products to treat various forms of cancer.”

Annual report 2025A · The company itself

“Our products are designed and manufactured in technology centers around the world, either by us or third parties. In most cases, the manufacturing of any specific product is concentrated in one or a few locations.”

Annual report 2025A · The company itself

“Idag installeras globalt cirka 1 200 linjäracceleratorer varje år. Av dessa har endast omkring 30 procent SGRT installerat från början. C-RAD är en av pionjärerna inom SGRT på den globala marknaden, och har i nuläget cirka 1900 installationer runt om i världen.”

Annual report 2024A · The company itself

“Fler än 1 900 (1 500) system har levererats globalt. Antalet system med serviceavtal ökade väsentligt under 2024.”

Annual report 2024A · The company itself

“Exempelvis har ett av Sveriges ledande universitetssjukhus, Lund, publicerat en studie om DIBH (Deep Inspiration Breathhold) med vårt SGRT-system. Vår DIBH-lösning VitalHold™ med fokus på bröstcancer, som vi utvecklat tillsammans med Accuray, används nu kliniskt i USA, Japan, Indien, Frankrike och Thailand.”

Annual report 2024A · The company itself

“En banbrytande teknologi som bidrar till en bättre cancervård C-RAD erbjuder positionerings- och skanningsprodukter som används inom avancerad strålterapi för att med extremt hög precision, säkerhet och effektivitet kunna leverera stråldosen till exakt rätt ställe i cancertumören.”

Annual report 2024A · The company itself

“Delårsrapport Q1 2025, 7 maj 2025 Årsstämma 2025, 8 maj 2025 Delårsrapport Q2 2025, 18 juli 2025 Delårsrapport Q3 2025, 23 oktober 2025 Bokslutskommuniké 2025, 10 februari 2026 Kontakt investerare cecilia.deleeuw@c-rad.com, VD linda.frolen@c-rad.com, CFO C-RAD utvecklar avancerade system för ytskanning som förbättrar precisionen vid strålbehandling av cancer. Företaget har sina rötter i svensk forskning inom strålterapi och erbjuder produkter som använder optisk ytskanningsteknik (SGRT).”

Annual report 2024A · The company itself

“Alla cancerpatienter ska ha bästa möjliga behandling Affärsidé / Mission C-RAD utvecklar och säljer innovativ ytskanningsteknologi (SGRT - Surface Guided Radiation Therapy) till kunder världen över. Våra produkter används för exakt positionering av patienter under strålningsbehandling av cancersjukdomar och bidrar till ökad livskvalitet för cancerpatienter världen över.”

Annual report 2024A · The company itself

“C-RAD har en omfattande serviceverksamhet med ett brett utbud av tjänster och kompetenser. Serviceverksamheten är en växande del av C-RADs erbjudande och antalet system som täcks av löpande servicekontrakt ökar kontinuerligt.”

Annual report 2024A · The company itself

“The manufacture of many of our products is a highly exacting and complex process, due in part to strict regulatory requirements. Problems can arise during manufacturing for a variety of reasons, including equipment malfunction, contamination, failure to follow specific protocols and procedures, problems with raw materials or components, cyber-attacks, natural disasters and environmental factors, and if not discovered before the product is released to market can result in recalls and product liability exposure.”

Annual report 2025A · The company itself

“The discovery and medical business is a leading provider of solutions to accelerate biotherapeutic research and discovery through high quality sample preparation and reliable diagnostic assays in addition to ensuring sterility and safety in medical liquids and gases. The business provides solutions and technologies for: lab filtration, separation and purification; lab-scale protein purification and analytical tools to support bio-molecular analysis, identification and characterization; reagents, membranes and services for diagnostic and assay development; and healthcare filtration solutions for drug delivery and patient care.”

Annual report 2025A · The company itself

“DIAGNOSTICS The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.”

Annual report 2025A · The company itself

“Manufacturing or design defects or “bugs” in, unanticipated use of, safety or quality issues (or the perception of such issues) with respect to, “off label” use of, or inadequate disclosure of risks relating to the use of products and services that we make or sell (including items that we source from third-parties) can lead to personal injury, death, property damage and/or regulatory violations that can adversely affect our business and financial statements. These events can lead to recalls or safety alerts, result in the removal of a product or service from the market and result in product liability, errors and omissions or similar claims being brought against us. Recalls, removals and product liability and similar claims (regardless of their validity or ultimate outcome) can result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products and services.”

Annual report 2025A · The company itself

“Certain of our products are medical devices and other products that are subject to regulation by the FDA, by other federal and state governmental agencies, by comparable agencies of other countries and regions, by certain accrediting bodies and by regulations governing hazardous materials and drugs-of-abuse (or the manufacture and sale of products containing any such materials).”

Annual report 2025A · The company itself

“•If we are unable to successfully complete the pre-clinical studies or clinical trials necessary to support additional PMA, de novo, or 510(k) applications or supplements, we may be unable to commercialize our CGM systems under development, which could impair our business, financial condition and operating results. •Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business. •We are subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief.”

Annual report 2025A · The company itself

“Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts on commercialization of our products, including growth of our manufacturing capacity, on research and development, and conducting clinical trials for our future products.”

Annual report 2025A · The company itself

“PART I ITEM 1 - BUSINESS Overview We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world.”

Annual report 2025A · The company itself

“The Federal Physician Self-Referral Law, also referred to as the Stark Law, prohibits a physician (or an immediate family member of a physician) who has a financial relationship with an entity from referring patients to that entity for certain designated health services, including durable medical equipment such as the CGM receiver and supplies, payable by Medicare, unless an exception applies.”

Annual report 2025A · The company itself

“Quality is very important to us and our customers due to the serious and costly consequences of product failure, and our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices. Since the first commercial launch of our products in 2006, we have had periodic field failures related to our products and associated services, including reports of sensor errors, sensor failures, broken sensors, receiver malfunctions, audible alarms and alert failures, as well as server and transmitter failures.”

Annual report 2025A · The company itself

“Based on our experience, complications from use of our products may include sensor errors, sensor failures, broken or detached sensor wires, or skin irritation under the adhesive dressing of the sensor. Inflammation or redness, swelling, minor infection, and minor bleeding at the sensor insertion site are also possible risks with an individual’s use of our products.”

Annual report 2025A · The company itself

“Since then we have received 510(k) clearances for modifications to the G6 and approval for G7 and G7 15 Day. In 2024, the FDA cleared Stelo as an over-the-counter biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin.”

Annual report 2025A · The company itself

“We expect our research and development expenses to increase in connection with our clinical trials and other development activities related to our products, including our next-generation sensors, transmitters and receivers, as well as other collaborations.”

Annual report 2025A · The company itself

“Såväl orderingång som försäljning påverkades positivt av god utveckling för bolag med kunder inom medicinteknik och läkemedel, processindustrin och energisegmentet.”

Annual report 2024A · The company itself

“De långsiktiga behoven är stora i många av våra branscher, exempelvis inom medicinteknik och läkemedel, infrastruktur och energisektorn.”

Annual report 2024A · The company itself

“Samtidigt har vi anpassningsbara bolag och därtill en förväntan om att en expansiv finans- och penningpolitik i många länder ska lägga grunden för gradvis ökad investeringsvilja hos våra kunder. De långsiktiga behoven är stora i många av våra branscher, exempelvis inom medicinteknik och läkemedel, infrastruktur och energisektorn.”

Annual report 2024A · The company itself

“LIFE SCIENCE MeHow är en utvecklingspartner och ledande tillverkare av formsprutade komponenter för den globala medicinteknikindustrin. Bolaget erbjuder ett brett sortiment av moduler baserade på formsprutade komponenter, dispenseringshållare för kardiovaskulära produkter som styrtrådar och katetrar samt verktygstillverkning till ledande internationella OEMkunder.”

Annual report 2024A · The company itself

“Life Science Den 31 januari förvärvades MeHow Medical Ireland Ltd., Irland, med en årsomsättning om 160 mkr. MeHow är en utvecklingspartner och tillverkare av formsprutade komponenter för den globala medicinteknikindustrin.”

Annual report 2024A · The company itself

“Nettoomsättning per kundsegment, % Nettoomsättning per produktområde, % Nettoomsättning per geografisk marknad, % Medicinteknik och läkemedelsindustri 77% Livsmedel 6% Verkstadsindustri 4% Energi 4% Processindustri 3% Övrigt 6% Medicinteknik 40% Rör & rörsystem 16% Ventiler 14% Filter & Processteknik 7% Mätteknik 6% Övrigt 17% Sverige 20% Danmark 20% Storbritannien & Irland 14% Benelux 12% Tyskland 6% Övrigt 28% % Nettoomsättning EBITA-marginal % Net sales EBITA-margin Affärsområdet omfattar både teknikhandelsbolag och bolag med egna produkter.”

Annual report 2024A · The company itself

“Den 2 juli förvärvades Miclev Medical Products AB, Sverige, med en årsomsättning om 130 mkr. Miclev är ett teknikhandelsbolag specialiserat inom renrumsprodukter.”

Annual report 2024A · The company itself

“Government Regulation United States FDA Regulation Our products are medical devices that are subject to extensive and ongoing regulation by the FDA and other federal, state, and local regulatory bodies. FDA regulations govern, among other things, product design and development, preclinical and clinical testing, pre-market clearance or approval, manufacturing, labeling, product storage, advertising and promotion, sales and distribution, post-market adverse event reporting, post-market surveillance, complaint handling, repair or recall of products, and record keeping.”

Annual report 2025A · The company itself

“Risk Factors Risks Related to Our Business We currently rely on sales of our Omnipod product platform to generate most of our revenue. We expect to continue to derive nearly all our revenue from our Omnipod product platform.”

Annual report 2025A · The company itself

“Nature of the Business Insulet Corporation (the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery system for people with insulin-dependent diabetes. The Company generates most of its revenue from sales of its Omnipod products.”

Annual report 2025A · The company itself

“Although the use of solutions for real-time blood flow measurement and ultrasound imaging during procedures is increasing, the vast majority are executed by surgeons merely relying on experience and physical finger palpation for graft patency assessment. Currently, only about 45 % of the global CABG market is utilizing support systems. Development of the overall market, by increasing acceptance and use of supporting technology such as Transit Time Flow Measurement (TTFM) and High-Frequency Ultrasound Imaging (HFUS) represents Medistim’s main growth opportunity.”

Annual report 2024A · The company itself

“Guidelines recommend intraoperative ultrasound after Carotid Endarterectomy (CEA) in 2022: The European Society of Vascular Surgery (ESVS) revised their Clinical Practice Guidelines in 2022 on the management of atherosclerotic carotid and vertebral artery disease by among others, adding a recommendation of the use of intra-operative completion control with ultrasound imaging, to reduce risk of perioperative stroke for patients undergoing carotid endarterectomy. The Guidelines are set to identify luminal thrombus after flow restoration, diagnose intimal flaps and diagnose residual stenoses during surgery.”

Annual report 2024A · The company itself

“A key to succeeding with winning in both Cardiac (CABG) and Vascular markets is continued innovation and product development. Customers expect to see improved performance from both the Flow and Imaging core technologies, as well as new features that will advance the clinical value and make the products even more user-friendly and attractive to build into their workflows.”

Annual report 2024A · The company itself

“The company invests between 4 % and 10 % of annual sales in research and development (R&D). In 2024, total R&D investments amounted to MNOK 35.0 (MNOK 29.0), corresponding to 7.4 % (6.5 %) of sales of own products.”

Annual report 2024A · The company itself

“7.3 Strategy Medistim’s strategic progress relies on strong clinical documentation, technology and product innovation and development, and the ability to effectively commercialize its product portfolio worldwide. Strong clinical studies by leading medical centers create support from KOLs, and it is a strategic priority to support this by sharpening the focus on blood flow measurements, ultrasound imaging, surgical guidance, and quality assurance in relevant forums and channels.”

Annual report 2024A · The company itself

“Continuous technology and product development are required to maintain and develop Medistim’s leading position within cardiac as well as vascular surgery, and the company plans to launch new products tailored to the specialties within these fields. The company is continuously strengthening all parts of its organization. This includes the sales, service, marketing and medical teams which interact directly with customers, and the innovation, R&D, QA & Regulatory, and manufacturing departments.”

Annual report 2024A · The company itself

“Convert Flow-only market to a Flow-and- Imaging market by establishing surgical guidance and quality assessment as the new standard of care through: a. Early adopter and KOL support b. REQUEST study c. Ease conversion from Flow to Imaging with MiraQ 2.”

Annual report 2024A · The company itself

“Achieve routine use of both Flow and Imaging by fighting ignorance, indifference and ease-of-use objections through: a. Clinical marketing, guidelines and educational programs b. Product innovation for ease of use c. Increased sales force capacity 3.”

Annual report 2024A · The company itself

“Build and strengthen position in vascular surgery through: a. Dedicated system (MiraQ Vascular) & probes b. Building position with societies and KOLs 5.”

Annual report 2024A · The company itself

“7.5 Research and development Medistim continuously invests in existing and new products to cover the surgical requirements for quality verification. The company invests between 4 % and 10 % of annual sales in research and development (R&D). In 2024, the company invested 7.4 % (6,5 % in 2023) of annual sales of own products in research and development (R&D).”

Annual report 2024A · The company itself

“Product development for increased “ease of use” In order to grow technology adoption, it is pivotal to make the products as easy to learn and use as possible. Medistim is therefore focusing on innovation to develop new features and ensure “ease of use” for the end-customer. The company’s innovation team collaborates closely with a network of surgeons and hospitals to test prototypes and new ideas.”

Annual report 2024A · The company itself

“Over the past four decades, Medistim’s mission has been to serve patients, surgeons and health care providers with innovative and cost-effective medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the quality and outcome of cardiac and vascular surgery.”

Annual report 2024A · The company itself

“Medistim is a market leader within intraoperative transit time flow measurement (TTFM) and ultrasound imaging, providing the MiraQ™ system to the global market.”

Annual report 2024A · The company itself

“The Medistim Group’s core business is within developing, producing, servicing, leasing and distributing medical devices.”

Annual report 2024A · The company itself

“The products distributed are medical devices within all types of surgery.”

Annual report 2024A · The company itself

“This has positioned Medistim to build a broader, Scandinavian distribution business for third party products.”

Annual report 2024A · The company itself

“The company’s long-term vision is stated as: Medistim is standard-of-care in the operating room. This implies, making Medistim’s solutions the standard-of-care in clinical practice for Coronary Artery Bypass Graft (CABG) surgery procedures and vascular surgery, ensuring that blood flow measurements and intraoperative ultrasound imaging are performed on all patients.”

Annual report 2024A · The company itself

“7.2 Medistim’s solutions Medistim’s devices are increasingly used to support CABG and other vascular surgical procedures. The solutions enable cardiac imaging, blood flow measurement and provides surgeons with immediate feed-back on procedure outcome. Intraoperative surgical guidance and quality assessment with ultrasonic imaging and blood flow measurement reduces risk of stroke for the patient. It also provides the surgeon with a tool to verify graft functionality, indicate when revisions are needed and to optimize graft strategy during surgery.”

Annual report 2024A · The company itself

“The offering is two-fold; 1) medical systems for monitoring and analysis, and 2) consumables, including re-usable cardiac and vascular probes and ultrasound imaging probes. Sales of consumable correlates to the number of procedures executed and is highly dependent on size of in-stalled base of systems.”

Annual report 2024A · The company itself

“The MiraQ™ is Medistim’s most advanced product line with configurations for both cardiac and vascular surgery. The MiraQ platform offers specialized configurations for cardiac and vascular applications in the products MiraQ Cardiac and MiraQ Vascular, respectively.”

Annual report 2024A · The company itself

“7.7 Market for cardiac procedures Percutaneous Coronary Intervention (PCI), i.e. the use of stents, covers approximately 80 % of the revascularization procedures, with CABG covering the remaining 20 %. Clinical trials document superior results achieved with CABG compared to PCI for patients with multi-vessel disease. The number of coronary artery bypass surgeries performed has been stable over the past several years, of more than 700 000 globally per annum.”

Annual report 2024A · The company itself

“Peripheral bypass surgery is primarily performed on the major arteries in the legs, whereas CEA is a procedure where blockages in the neck arteries are surgically removed to reduce risk of stroke. AV access surgery is performed to create a successful shunt or fistula that are used to connect a patient in need of dialysis to a dialysis machine. The MiraQ Vascular solution supports all three types of interventions with ultrasound imaging and blood flow measurements guiding the surgeon during the procedure to assure the quality of the clinical outcome.”

Annual report 2024A · The company itself

“If the supply of certain pharmaceuticals provided by one or more of our vendors were to be disrupted for any reason, our pharmacy operations could be severely affected until at least such time as we could obtain a new supplier for such pharmaceuticals. Any such disruption could cause reputational damage and result in a significant number of our pharmacy customers transferring their prescriptions to other pharmacies. One or a combination of the factors above may adversely affect the volumes of brand name and generic pharmaceuticals we sell, our cost of sales associated with our retail pharmacy operations, the net sales and gross margin of those operations or result in the loss of cross-store or cross-club selling opportunities.”

Annual report 2026A · The company itself

“Our health and wellness operations in the U.S. are subject to numerous federal, state and local laws and regulations including, but not limited to, those related to: licensing; reimbursement arrangements and other requirements and restrictions; registration and regulation of pharmacies; dispensing and sale of controlled substances and products containing pseudoephedrine; governmental (including Medicare and Medicaid) and commercial reimbursement; data privacy and security and the sharing and interoperability of data, including obligations and restrictions related to health information (such as those imposed under HIPAA); protection of consumer health data; billing and coding for healthcare services and properly handling overpayments; debt collection; necessity and adequacy of healthcare services; relationships with referral sources and referral recipients and other fraud and abuse issues, such as those addressed by anti-kickback and false claims laws and patient inducement regulations; qualification of healthcare practitioners; quality and standards of medical services and equipment; and the practice of the professions of pharmacy and optometry.”

Annual report 2026A · The company itself

“The design, manufacturing and marketing of pharmaceutical packaging and medical devices involve certain inherent risks. Manufacturing or design defects, unanticipated use of our products, or inadequate disclosure of risks relating to the use of our products can lead to injury or other adverse events.”

Annual report 2025A · The company itself

“Key value-added and proprietary products and processes are licensed from our affiliate, Daikyo, including but not limited to, Crystal Zenith, FluroTec® and B2-coating technologies. Our rights to these products and processes are licensed pursuant to agreements that expire in 2027.”

Annual report 2025A · The company itself

“We continue to pursue strategic initiatives in drug containment components, integrated drug containment systems, novel drug delivery devices, novel therapeutic experiences and administration systems.”

Annual report 2025A · The company itself

“BUSINESS General We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products.”

Annual report 2025A · The company itself

“Our packaging products include stoppers and seals for injectable packaging systems, which are designed to help ensure drug compatibility and stability with active drug products, while also supporting operational efficiency for customers. These packaging products also include syringe and cartridge components, including custom solutions for the specific needs of injectable drug applications, as well as administration systems that can enhance the safe delivery of drugs through advanced reconstitution, mixing and transfer technologies.”

Annual report 2025A · The company itself

“In addition, we offer a variety of self-injection devices, designed to address the need to provide at-home delivery of injectable therapies. These devices are patient-centric technologies that are easy-to-use and can be combined with connected health technologies that have the potential to increase adherence.”

Annual report 2025A · The company itself

“Contract-Manufactured Products Segment Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.”

Annual report 2025A · The company itself

“Our growth partly depends on new-product innovation and the development and commercialization of proprietary multi-component systems for injectable drug administration and other healthcare applications.”

Annual report 2025A · The company itself

“In addition, the timely and adequate availability of filling capacity is essential to both conducting definitive stability trials and the timing of commercialization of customers’ products in Crystal Zenith vials, syringes and cartridges.”

Annual report 2025A · The company itself

“Our Contract-Manufactured Products customers include many of the world’s largest pharmaceutical, diagnostic, and medical device companies.”

Annual report 2025A · The company itself

“Den dominerande kundsektorn är medicinteknik- och läkemedelsindustrin med världsledande företag som utmanande kravställare. Försäljningen till försvarsindustrin utgör en växande andel.”

Annual report 2024A · The company itself

“Komponenter till röntgen- och dialys utrustning, produkter för hantering och förvaring av läkemedel, mjukvarulösningar för kontroll av produktionsflöden, högteknologiska och flexibla produktionslösningar för förpackningsprocesser.”

Annual report 2024A · The company itself

“Andra viktiga kundsegment är medicinteknik, infrastruktur och energi.”

Annual report 2024A · The company itself

“Hög teknisk kompetens i kombination med spjutspetsteknologi inom skärande bearbetning innebär att företaget kan erbjuda skräddarsydda produktionslösningar, framför allt som kontraktstillverkare mot de stora medicinteknikföretagen samt inom försvars-, flyg- och rymdindustri.”

Annual report 2024A · The company itself

“Lasertechs kundstruktur omfattar företag inom branscher som fordon, försvar och medicinteknik.”

Annual report 2024A · The company itself

“Kunderna finns huvudsakligen i Europa och utgörs av ledande företag inom läkemedel och medicinteknik samt hälso- och sjukvård.”

Annual report 2024A · The company itself

“Reportable Segments Manufacturing Sites Medical Devices 33 Diagnostic Products 21 Established Pharmaceutical Products 22 Nutritional Products 13 Worldwide Total 89 Abbott’s research and development facilities in the United States are primarily located in California, Illinois, Minnesota, New Jersey, and Ohio.”

Annual report 2025A · The company itself

“Inom Medtech har AddLife identifierat prioriterade tillväxtsegment som förväntas bidra till resultattillväxten. Bland annat utgör ortopedi och endoskopi, med marginaler på över 10 procent, prioriterade tillväxtsegment för affärsenheten Hospital.”

Annual report 2023A · The company itself

“Drivet av ökad aktivitet inom den planerade kirurgi steg efterfrågan inom främst produktområdena ortopedi, kirurgi, respiration och endoskopi.”

Annual report 2023A · The company itself

“Under tredje kvartalet förvärvade AddLife samtliga aktier i bolaget Emmat Medical Ltd. Det förvärvade bolaget, som kommer att integreras med Healthcare 21 Groups verksamhet i Storbritannien, är verksamt inom kirurgi och omsätter cirka 28 MSEK med god lönsamhet och tillväxtpotential.”

Annual report 2023A · The company itself

“ROPOX FÖRBÄTTRAR LIVET FÖR DEM MED FUNKTIONSVARIATION Ropox har över 60 års erfarenhet av att ta fram produkter som hjälper människor att leva ett självständigt liv. De är världsledande specialister och tillverkare av hjälpmedel och möbler, och de erbjuder skräddarsydda lösningar som underlättar för användarna och deras familjer. Ropox erbjuder ett omfattande utbud av bostadsanpassningar, vilka gör det möjligt för personer med funktionsvariation att leva ett mer självständigt liv.”

Annual report 2023A · The company itself

“Accident 18.9 % 19.6 % Disability 26.4 26.3 Critical care (1) 19.8 20.9 Hospital indemnity 13.2 13.7 Dental/vision 6.2 5.3 Life 15.5 14.2 Total 100.0 % 100.0 % (1) Includes cancer, critical illness and hospital intensive care products In 2025, the Aflac U.S. sales force included an average of approximately 5,300 U.S. agents, including brokers, who were actively producing business on a weekly basis.”

Annual report 2025A · The company itself

“("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.”

Annual report 2025A · The company itself

“Fourth, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry, in situ hybridization, hematoxylin and eosin staining and special staining. This business further provides clinical flow cytometry reagents for routine cancer diagnostics. This business also provides bulk antibodies as raw materials and associated assay development services to in vitro diagnostics manufacturers, biotechnology and pharmaceutical companies.”

Annual report 2025A · The company itself

“Fifth, we also collaborate with several major pharmaceutical companies to develop new potential tissue pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy.”

Annual report 2025A · The company itself

“Pathology This area consists of routine clinical solutions for tissue-based cancer diagnostics with solutions that comprise antibodies, reagents, instruments and software targeting both primary and advanced cancer diagnostics. Our CoverStainer and Artisan based product families target primary cancer diagnostics through hematoxylin and eosin staining as well as special stains for additional insights and detection of potentially carcinogenic tissue. Dako Omnis and Autostainer based immunohistochemistry solution and instant quality fluorescence in situ hybridization technologies provide advanced tumor typing through investigation of protein and gene expression.”

Annual report 2025A · The company itself

“These products also include companion diagnostic tests that are used to help identify patients most likely to benefit from a specific targeted therapy.”

Annual report 2025A · The company itself

“Our bulk antibodies business partners with in vitro diagnostics manufacturers, biotechnology and pharmaceutical companies by offering antibodies as raw materials and a range of associated assay development services and solutions.”

Annual report 2025A · The company itself

“In the area of flow cytometry reagents we provide reagents and kits directly to clinical laboratories working in routine cancer diagnostics, with particular focus on blood cancers.”

Annual report 2025A · The company itself

“Table of Contents Companion Diagnostics In our companion diagnostics business, we partner with several major pharmaceutical companies to develop new potential pharmacodiagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. We support pharmaceutical companies during each phase of their drug development process, from early pre-clinical through commercial launch activities.”

Annual report 2025A · The company itself

“Regained sales to the auto industry in Europe combined with a continued increase in sales of products for filtration solutions and products for the Med- Tech industry also added to revenue.”

Annual report 2025A · The company itself

“The exteriors of our properties typically resemble traditional office properties, but the interior infrastructures are designed to accommodate the needs of life science tenants. These improvements typically are generic rather than specific to a particular tenant. As a result, we believe that the improvements have long-term value and utility and are usable by a wide range of tenants.”

Annual report 2025A · The company itself

“Stable Cash Flows From Our High-Quality and Diverse Mix of Tenants Investment-Grade or Publicly Traded Large Cap Tenants 84% of ARE’s Top 20 Tenant Annual Rental Revenue 53% of ARE’s Total Annual Rental Revenue Life Science Product, Service, and Device Multinational Pharmaceutical Public Biotechnology - Approved or Marketed Product Other(1) Advanced Technologies(2) Public Biotechnology - Preclinical or Clinical Stage Government Institutions Biomedical Institutions(3) Private Biotechnology Percentage of ARE’s Annual Rental Revenue As of December 31, 2025.”

Annual report 2025A · The company itself

“(“we,” “us,” “our,” “Align” or the “Company”) is a global medical device company primarily engaged in the design, manufacture and marketing of Invisalign® clear aligners for the treatment of malocclusions, or the misalignment of teeth, by orthodontists and general dental practitioners (“GPs”), ViveraTM retainers for retention, iTeroTM intraoral scanners and services for dentistry, and exocadTM computer-aided design and computer-aided manufacturing (“CAD/CAM”) software for dental laboratories and dental practitioners.”

Annual report 2025A · The company itself

“Sales and Marketing Our sales and marketing efforts are focused on increasing adoption and utilization of the Invisalign System and Vivera retainers by orthodontists and GPs and integrating the iTero scanner and services and exocad CAD/CAM products into dental labs and practices.”

Annual report 2025A · The company itself

“The iTero scanner is an important component to the customer experience and is central to a digital approach as well as overall customer utilization of Invisalign clear aligners.”

Annual report 2025A · The company itself

“Our business exposes us to potential liability for the quality and safety of our products and services, how we advertise and market those products and services, and how and to whom we sell them, and we may incur substantial expenses or be found liable for substantial damages or penalties if we are subject to claims or litigation. Our products and services involve an inherent risk of claims concerning their design, materials, manufacture, safety, and performance, how we package, bundle, or sell them to individual customers or companies, including hospitals and clinics, and how we train and support doctors, their staffs and patients who use our products and services.”

Annual report 2025A · The company itself

“Anaphylaxis & other products, DKK 832 million, 34% organic growth”

Annual report 2025B · From the report

“Anaphylaxis & other products ( neffy ® , diagnostics, PRE-PEN ® , and life science products) grew by 34%”

Annual report 2025A · The company itself

“ALK markets a diversified portfolio of products, including allergy immunotherapy (AIT) tablets, injections, and drops as well as adrenaline autoinjectors and nasal sprays.”

Annual report 2025A · The company itself

“Särskilt allvarligt är det om skyddsutrustning såsom exempelvis varselkläder, flamskyddsplagg och skyddsskor brister i kvalitet och utförande.”

Annual report 2024A · The company itself

“Our Anesthesia & Patient Monitoring business accounted for 40% of Ambu’s total revenue in 2024/25.”

Annual report 2025A · The company itself

“a high-growth MedTech company, we remain focused on driving growth, while balancing investments with scalable operations.”

Annual report 2025A · The company itself

“ArcticZymes’ ligase prototypes, polymerases, and pipeline innovations, including DNA assembly, show great promise for future utility in this market. • Liquid Biopsies – DNA or other diagnostics tests are performed on blood or other body fluids. The market is growing (CAGR 11.9%) with an estimated market size of USD 6.4 Billion. Unlike traditional invasive biopsies, liquid biopsies require a whole new set of molecular techniques to overcome the challenges of isolating tiny amounts of DNA and amplifying it sufficiently to allow diagnostic insights to be derived.”

Annual report 2024A · The company itself

“ArcticZymes sales revenues are from sales of enzymes for use in molecular research, In Vitro Diagnostics and Biomanufacturing.”

Annual report 2024A · The company itself

“Säkra produkter av hög kvalitet är Arjos signum vilket bolaget hela tiden arbetar för att säkerställa.”

Annual report 2024A · The company itself

“Om Orviglance Orviglance (manganklorid-tetrahydrat) är ett first-in-class oralt kontrastmedel för magnetkameraundersökningar som är utvecklat för att förbättra upptäckten och visualiseringen av fokala leverskador (inklusive levermetastaser och primära tumörer) hos patienter med nedsatt njurfunktion. Dessa patienter riskerar allvarliga biverkningar från den nuvarande tillgängliga klassen av gadoliniumbaserade kontrastmedel.”

Annual report 2024A · The company itself

“För Ascelia Pharma blir drivkraften för ett alternativ till gadolinium, Orviglance, bättre och bättre. Orviglance är det enda MR-kontrastmedlet utan gadolinium i sen utvecklingsfas och förväntas vara först i klassen för att leda en mer hållbar framtid med mindre gadolinium.”

Annual report 2024A · The company itself

“Alliance Revenue, comprising our share of gross profits, share of revenues and royalties, increased in the year by 39% (CER: 38%), to $3,067 million, including $1,798 million from Enhertu and $673 million from Tezspire , which achieved blockbuster status in 2024.”

Annual report 2025A · The company itself

“BD Medical consists of the following organizational units: Table of Contents Organizational Unit Principal Product Lines Medication Delivery Solutions Peripheral intravenous (“IV”) catheters (conventional, safety); advanced peripheral catheters (guidewire assisted peripherally inserted venous catheters, midline catheters, port access); central lines (peripherally inserted central catheters); acute dialysis catheters; vascular access technology (ultrasonic imaging); vascular care (lock solutions, prefilled flush syringes, disinfecting caps); vascular preparation (skin antiseptics, dressings, securement); needle-free IV connectors and extensions sets; closed-system drug transfer devices; hazardous drug detection; conventional and safety hypodermic syringes and needles, anesthesia needles (spinal, epidural) and trays; enteral syringes; and sharps disposal systems.”

Annual report 2025A · The company itself

“Medication Management Solutions IV medication safety and infusion therapy delivery systems, including infusion pumps, dedicated disposables, and IV fluids; medication compounding workflow systems; automated medication dispensing; automated supply management systems; medication inventory optimization and tracking systems; informatics and analytics solutions for enterprise medication management; and pharmacy automation systems.”

Annual report 2025A · The company itself

“Pharmaceutical Systems Prefillable drug delivery systems - prefillable syringes, safety, shielding and self-injection systems and support services (combination product testing, technical and regulatory) - provided to pharmaceutical companies for use as containers for injectable pharmaceutical products, which are then placed on the market as drug/device combinations.”

Annual report 2025A · The company itself

“Advanced Patient Monitoring Advanced hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings, including noninvasive tissue oximetry systems; hemodynamic and tissue oximetry monitoring systems; pulmonary artery catheters and arterial pressure monitoring products and blood pressure measurement systems.”

Annual report 2025A · The company itself

“BD Life Sciences BD Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, BD Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes.”

Annual report 2025A · The company itself

“BD Life Sciences consists of the following organizational units: Table of Contents Organizational Unit Principal Product Lines Diagnostic Solutions Automated blood culturing and tuberculosis culturing systems; microorganism identification and drug susceptibility systems; microbiology laboratory automation and informatics; dehydrated, liquid and plated media for clinical and industrial microbiology applications; molecular testing systems for infectious diseases and women’s health; and rapid diagnostic assays for testing of respiratory infections at point of care.”

Annual report 2025A · The company itself

“Biosciences Fluorescence-activated cell sorters and analyzers; antibodies and kits for performing cell analysis; reagents for life science research; solutions for high-throughput single-cell gene and protein expression analysis; and clinical oncology, immunological (HIV) and transplantation diagnostic/monitoring reagents, analyzers and informatics.”

Annual report 2025A · The company itself

“Specimen Management Blood collection systems including safety-engineered wingsets, needles and blood collection tubes, arterial blood gas devices, urine collection kits, molecular research tubes, capillary collection technologies alongside associated products for patient identification,data capture, storage and transportation.”

Annual report 2025A · The company itself

“BD Interventional BD Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by BD Interventional are hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via our Homecare business.”

Annual report 2025A · The company itself

“Peripheral Intervention Percutaneous transluminal angioplasty (“PTA”) balloon catheters, radio frequency ablation catheters, peripheral vascular stents, self-expanding and balloon-expandable stent grafts, vascular grafts, drug coated balloons, ports, biopsy, chronic dialysis, inferior vena catheter filters, endovascular fistula creation devices and drainage products, and atherectomy and thrombectomy systems. Urology and Critical Care Urine management and measurement devices, indwelling, intermittent and external urine catheters, kidney stone management devices, Targeted Temperature Management, and fecal management devices.”

Annual report 2025A · The company itself

“BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; and advancing cellular research and applications.”

Annual report 2025A · The company itself

“BD Medical BD Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by BD Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers.”

Annual report 2025A · The company itself

“Kundbasen är väldiversifierad med företag i sektorer som verkstad, fordon, medicinteknik och infrastruktur.”

Annual report 2024A · The company itself

“Till de områden som hade en särskilt fin utveckling hör Beijer Techs nischbolag samt Lesjöfors verksamhet inom medicinteknik.”

Annual report 2024A · The company itself

“Flera av bolagen påverkas inte direkt av industrikonjunkturen, exempelvis Chassifjädrar, medicinteknik inom Lesjöfors samt bolagen i Beijer Techs affärsområde Nischteknologier.”

Annual report 2024A · The company itself

“Medicinteknik är i fokus för Lesjöfors som driver en lönsam, organisk tillväxt.”

Annual report 2024A · The company itself

“I Slovakien har vi gjort en anpassning av vår fabrik så den möter de särskilda krav som ställs på medicinteknisk tillverkning.”

Annual report 2024A · The company itself

“Lubrizol Additives’ products are used in a broad range of applications including engine oils, transmission fluids, gear oils, specialty driveline lubricants, fuels, metalworking fluids and compressor lubricants for transportation and industrial applications. Lubrizol Advanced Materials’ products are used in many different types of applications including beauty, personal care, home care, over-the-counter pharmaceuticals, medical devices, performance coatings, sporting goods, plumbing and fire sprinkler systems.”

Annual report unknown yearA · The company itself

“The Medical group develops, manufactures and sells a wide range of innovative medical devices in the extremities fixation, craniomaxillofacial surgery, neurosurgery, aesthetics and cardiac rehabilitation markets. The group’s leading-edge medical technology and products are used globally to help improve patient care and outcomes.”

Annual report unknown yearA · The company itself

“TTI services a variety of industries including telecommunications, medical devices, computers and office equipment, military/aerospace, automotive and industrial electronics.”

Annual report unknown yearA · The company itself

“Corporate Governance Statement 2025 11 Information for Shareholders 17 Board of Directors 18 Group Management Team 20 Financial Statements 21 Biohit in Brief Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products.”

Annual report 2025A · The company itself

“Sales of rapid tests increased by 28.7% compared with the previous year.”

Annual report 2025A · The company itself

“Growing Momentum for GastroPanel ® Biohit’s flagship product and most important growth driver is GastroPanel ® . Its value proposition is clear: GastroPanel ® enables accurate and reliable diagnosis of upper gastrointestinal symptoms in primary healthcare.”

Annual report 2025A · The company itself

“In November 2025, we refined our strategy with an increased focus on execution over the next three years. Our focus is on driving market adoption of the NGAL biomarker based primarily on research use only in the US, capturing high growth in North America and the EU, and expanding our addressable market.”

Annual report 2025A · The company itself

“The “Forward” strategic plan focuses on building market adoption, capturing high growth and expanding the addressable market during the next three years with distinct milestones every year.”

Annual report 2025A · The company itself

“An important element in BioPorto’s commercialization plan is to secure strategic distribution partnerships with clinical chemistry instrument manufacturers to drive instrument expansion that are FDA cleared for ProNephro AKI® (NGAL) use to enable more laboratories to implement the test and hence increase the serviceable market. In August 2025, the delivery of the first ProNephro AKI (NGAL) order to the US market, marked the first step in the commercial launch via a strategic distribution partnership.”

Annual report 2025A · The company itself

“We achieved 11% sales growth, mainly driven by continued growth in our research use only NGAL business in the United States.”

Annual report 2025A · The company itself

“Jens Due Olsen & Carsten Buhl Chairman of the Board & Chief Executive Officer A key strategic milestone, was the commercial launch of ProNephro AKI® on the Roche Cobas® c 501 module for the US pediatric market during Q3 2025. This launch aligns with our ambition to establish a commercial platform for kidney diagnostics and drive broad adoption of ProNephro AKI, the NGAL biomarker focused on AKI within the intensive care settings at hospitals globally.”

Annual report 2025A · The company itself

“For 2026, the main growth driver is expected to be NGAL in the U.S. for Research Use Only (RUO). Further, while commercialization of The NGAL TestTM and ProNephro AKI (NGAL) will be the primary contributor for growth, BioPorto expects stable revenue from its antibodies business.”

Annual report 2025A · The company itself

“BXLS invests across the life cycle of companies and products within the life sciences sector.”

Annual report 2025A · The company itself

“For example, • BXLS’s strategies include, among others, investments that are referred to as “corporate partnership” transactions. Corporate partnership transactions are risk-sharing collaborations with biopharmaceutical and medical device partners on drug and medical device development programs and investments in royalty streams of pre-commercial biopharmaceutical products.”

Annual report 2025A · The company itself

“Liiketoiminta-alueen yhtiöt ovat Yleiselektroniikka, YE International, Noretron Komponentit, Milcon, Infradex, Signal Solutions Nordic (SSN) sekä Delfin Technologies (Delfin).”

Annual report 2024A · The company itself

“The result for fine chemical intermediates improved compared with 2023, mainly due to higher sales volume.”

Annual report 2024A · The company itself

“Bolaget är en av få aktörer på den globala diagnostikmarknaden som utvecklar, tillverkar och marknadsför instrument och förbrukningsvaror för bloddiagnostik.”

Annual report 2024A · The company itself

“Om Boule / Boule Diagnostics AB (publ) Pålitlig partner för hematologidiagnostik och förbrukningsvaror Boule fokuserar på marknaden för decentraliserad, stationär hematologisk analys för humana och veterinära behov.”

Annual report 2024A · The company itself

“39% Förbrukningsvaror 28% Instrument 23% OEM Vi erbjuder ett brett sortiment av produkter genom våra välkända varumärken, Medonic™ och Swelab™ för humandiagnostik och Exigo™ för veterinärdiagnostik.”

Annual report 2024A · The company itself

“Instrumenten är utformade för att hålla i många år och förbrukningsvaror till installerade instrument utgör en betydande del av Boules försäljning.”

Annual report 2024A · The company itself

“Jan Feb Mar Apr Maj Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr Maj Jun Jul Aug Sep Oct Nov Dec 2023 2024 Boule Diagnostics Omsättnings volym (dagligen) AKTIEINVESTERING • Stark position på global nischmarknad Antal aktier Det totala antalet aktier och röster i Boule Diagnostics AB är 38,833,104 • Marknadstillväxt driven av grundläggande trender • Omfattande installerad instrumentbas ger återkommande intäkter • Växande OEM-försäljning • Lansering av uppdaterad plattform och utökat erbjudande samt högkvalitativa produkter • Hög kundnöjdhet Boule Diagnostics AB (publ) / Hållbarhet Hållbarhetsrapport Boule levererar lösningar för bloddiagnostik som används både vid hälsokontroller och diagnos av sjukdomar.”

Annual report 2024A · The company itself

“Verksamheten Koncernens verksamhet är primärt inriktad mot blodcellsräkning, hematologi, vilket är ett medicinskt område som fokuserar på studier av blodet, blodsjukdomar och en rad olika sjukdomar som kan diagnostiseras via blodanalys. Om en läkare träffar en patient med otydlig sjukdomsbild kan blodet analyseras med hjälp av ett automatiserat system för blodcellräkning. Avvikelser från normal nivå för de tre olika blodcelltyper som finns i blodet kan ge en bred bild av hälsostatus och indikera ett flertal olika sjukdomstillstånd. Blodcellräkning är idag en av världens vanligaste diagnostiska test på kliniska laboratorier och analyser genomförs inom såväl human- som veterinärdiagnostik.”

Annual report 2024A · The company itself

“Boules affärsmodell bygger på att sälja instrument för blodcellräkning på den globala hematologimarknaden och sedan ta del av återkommande intäktsströmmar genom att sälja engångsprodukter i form av reagenser, kontroller, kalibratorer, service och support till instrumenten. Instrumenten är optimerade för och låsta till egna reagenser vilket skapar ökad kvalitetssäkring av analysresultat och driftsäkerhet samt återkommande intäkter under instrumentens livslängd.”

Annual report 2024A · The company itself

“Bolagets erbjudande omfattar idag de fyra viktigaste organen inom transplantationsområdet: hjärta, lunga, lever och njure.”

Annual report 2024A · The company itself

“Branschen växer årligen med cirka 10% och har fortfarande stor utvecklingspotential eftersom många hjärtstartare inte fungerar när de behövs som mest. ”Ett stort problem är att 30-40% av alla hjärtstartare som finns utplacerade inte fungerar.”

Annual report 2024A · The company itself

“För att komma till rätta med detta har Safe Life utvecklat en affärsmodell med hyresupplägg och serviceavtal för regelbunden översyn. Uppläggen säkerställer att livsviktig utrustning fungerar och ger kunderna en långsiktig trygghet. ”Vi tar ansvar för att elektroder och batterier byts i regelbundna intervaller och därigenom säkerställer att hjärtstartaren fungerar när den behövs som mest.”

Annual report 2024A · The company itself

“Här fyller Safe Life en avgörande funktion. Foto: Liisa Eelsoo ” S edan grundarna Jimmy Eriksson och Alexander Albedj startade bolaget 2019, har Safe Life vuxit kraftigt.”

Annual report 2024A · The company itself

“En bransch under utveckling Safe Life är specialiserat på hjärtstartare eller AED:er som är en förkortning av automatisk extern defibrillator, och andra livräddande tjänster såsom t ex HLR-utbildning. Hittills har bolaget placerat över 500 000 hjärtstartare.”

Annual report 2024A · The company itself

“Core EDA Our Core EDA products and solutions are essential in the design and verification of semiconductor chips, including analog, digital, mixed-signal, memory, radio-frequency (“RF”), and silicon photonics, and are widely used across multiple industries including automotive, aerospace and defense, consumer electronics, data centers, industrial, medical, and mobile.”

Annual report 2025A · The company itself

“Other Operating Segments Our Nuclear and Precision Health Solutions operating segment operates nuclear pharmacies and manufacturing facilities, which manufacture, prepare, and deliver radiopharmaceuticals for use in nuclear imaging, theranostics, and other procedures in hospitals and physician offices. This segment also contract manufactures a radiopharmaceutical treatment (Xofigo®) and holds the rights to manufacture and distribute Lymphoseek®, a radiopharmaceutical diagnostic imaging agent.”

Annual report 2026A · The company itself

“Skadeståndskrav kan uppstå om bolagets produkter inte uppfyller gällande kvalitetskrav. CellaVision begränsar produktansvarsriskerna genom att följa rutiner för kvalitetssäkring samt genom omfattande tester av bolagets produkter.”

Annual report 2024A · The company itself

“Produktutveckling Fortsatt utveckling av befintliga och nya produkter och lösningar är av stor betydelse för CellaVision. Om bolagets förmåga att utveckla produkter upphör eller om produkter inte kan lanseras i enlighet med fastställda tidsplaner eller om mottagandet på marknaden blir sämre än förväntat kan detta medföra negativa effekter på CellaVisions försäljnings- och resultatutveckling.”

Annual report 2024A · The company itself

“Operativa risker Operativa risker är främst förknippade med produktutveckling, regulatoriska frågor och distribution. För att genomföra CellaVisions strategi och upprätthålla hållbara resultat krävs förmågan att kontinuerligt förse marknaden med innovativa produkter som möter kundernas behov. Därför gör CellaVision betydande investeringar i produktutveckling och har ett nära samarbete med distributionspartners och slutkund för att förstå förväntningarna och upptäcka nya möjligheter till innovation.”

Annual report 2024A · The company itself

“Företagets indirekta försäljningsmodell, som bygger på distribution via partners, understryker vikten av att främja en nära relation och samarbete med distributionspartners. Inom produktutveckling är regulatoriska frågor särskilt betydelsefulla eftersom godkännanden måste erhållas för att kunna sälja produkterna.”

Annual report 2024A · The company itself

“Enterprise Risk Management - 54 - Operativa risker Produktutveckling CellaVisions långsiktiga intjäning och konkurrenskraft beror på förmågan att utveckla innovativa produkter och lösningar som möter kundernas efterfrågan. Investeringar i produktutveckling styrs av företagets strategi och stöds av regelbunden uppföljning av roadmaps för hårdvara och mjukvara.”

Annual report 2024A · The company itself

“Operationella riskfaktorer Affärsmodell CellaVisions strategi är att etablera strategiska allianser med globala aktörer inom medicinsk teknik. CellaVision verkar genom distributörer på globala marknader. Detta innebär att CellaVisions framtida expansion är beroende av framgångsrika distributörer.”

Annual report 2024A · The company itself

“En av våra viktigaste fokusområden framöver blir den ökade användningen av vårt senaste digitala bildsystem. Med CellaVision ® DC-1 erbjuder vi ett kompakt analysinstrument som är perfekt anpassat för laboratorier med lägre provvolymer.”

Annual report 2024A · The company itself

“Återkoppling från kunder utvärderas och används för att hela tiden förbättra säkerheten och kvaliteten på våra produkter. Säkerheten förbättras ytterligare genom fortlöpande, strukturerad utbildning av personal och distributörer, både online och genom fysiska möten. den egna arbetskraften Koncernledningen har fortfarande en ojämn könsfördelning.”

Annual report 2024A · The company itself

“CellaVision säljer analysinstrument där mjukvara ingår samt reagenser för provberedning. Mjukvarorna fungerar ej som fristående produkter och reagenserna säljs till samma kundbas som instrumenten.”

Annual report 2024A · The company itself

“Strategi - The Power of Focus - 16 - MAXIMERA - Stora laboratorier Maximera vår ledande ställning inom stora laboratorier Att etablera nya standarder inom hematologilaboratorier har alltid varit ett av våra viktigaste fokusområden. Vi strävar efter att förfina och förbättra processen för blodcellsdifferentiering, med målet att optimera arbetsflöden, kvalitet och nätverk inom mikroskopi.”

Annual report 2024A · The company itself

“AccelERERA - Små och medelstora laboratorier Accelerera det globala användandet av CellaVision ® DC-1 Vid introduktionen av automatisering och digital bildbehandling inom cellmorfologi utvecklade vi konceptet digital cellmorfologi. Detta koncept omfattar nu en familj av avancerade och intelligenta digitala system, anpassade även för små och medelstora laboratorier.”

Annual report 2024A · The company itself

“Other Our Other segment includes: •Specialty Pharmacy. AcariaHealth provides specialty pharmacy services for patients with complex and chronic conditions.”

Annual report 2025A · The company itself

“•Vision and Dental Services. Our fully integrated vision and dental health programs include benefits beyond traditional medical benefits.”

Annual report 2025A · The company itself

“Magellan Health, Inc. (Magellan Health) supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life.”

Annual report 2025A · The company itself

“Our strategy is to deliver a comprehensive and integrated portfolio of drug discovery and non-clinical development products, services and solutions to support our clients’ discovery, preclinical, early clinical and early stage scale up and early stage manufacturing efforts, and enable them to bring new and improved therapies to market faster and more cost effectively.”

Annual report 2025A · The company itself

“Our DSA segment provides services that enable our clients to outsource their innovative drug discovery research, their related non-clinical and clinical bioanalytical activities, and regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines and medical devices.”

Annual report 2025A · The company itself

“Safety Assessment. We offer a full range of safety assessment studies required for regulatory submission on a global basis across all therapeutic areas in the pharmaceutical, biotechnology, industrial chemical, agrochemicals, consumer products, veterinary medicines and medical devices industries.”

Annual report 2025A · The company itself

“The ability to identify and characterize clinical and anatomic pathologic changes is critical in determining the safety and efficacy of potential new therapeutics, industrial and agricultural chemicals, veterinary medicines, and medical devices. Key “go/no-go” decisions regarding continued product development are typically dependent on the identification, characterization and evaluation of fluid, tissue and cellular changes that our experts identify and interpret for our clients.”

Annual report 2025A · The company itself

“We are a market leader in endotoxin testing products and services, which are used for globally, including FDA, required quality control testing of injectable drugs and medical devices, their components, and the processes by which they are manufactured.”

Annual report 2025A · The company itself

“Clients Our clients consist primarily of major biopharmaceutical companies; many small, emerging, and established biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, government agencies, and non-governmental organizations.”

Annual report 2025A · The company itself

“ChemoMetec tilbyder højkvalitets analyseudstyr, der optimerer workflows hos vores kunder”

Annual report 2025A · The company itself

“Omsætning fordelt på produktgrupper ... Instrumenter”

Annual report 2025B · From the report

“Omsætningen af forbrugsvarer steg fra DKK 192,5 mio. til DKK 230,8 mio.”

Annual report 2025B · From the report

“Inden for serviceforretningen (serviceaftaler, installationer, flytninger mv.) steg omsætningen med 21%”

Annual report 2025A · The company itself

“In particular, the FDA and foreign counterparts regulate the formulation, safety, development, manufacturing, packaging, labeling and distribution of condoms, home pregnancy test kits, vaginal lubricants, electric and battery powered medical devices, wound dressings, over-the-counter medicines, homeopathic products and dietary supplements.”

Annual report 2025A · The company itself

“9.9 bn reported revenue 6% organic growth”

Annual report 2025A · The company itself

“9.0 bn reported revenue 8% organic growth”

Annual report 2025A · The company itself

“2.8 bn reported revenue 2% organic growth”

Annual report 2025A · The company itself

“3.9 bn Reported revenue 8% organic growth”

Annual report 2025A · The company itself

“2.3 bn reported revenue 9% organic growth”

Annual report 2025A · The company itself

“Coloplast initiated a preventative and voluntary product return in Q3 of all Biatain® Adhesive foam dressings in China, following a local inspection where three product lots did not meet a technical requirement. Product safety was not compromised, and the dressings continue to meet standards in other markets.”

Annual report 2025A · The company itself

“In Kidney & Bladder Health, the thulium fiber laser, Coloplast TFL Drive continued to deliver a solid growth contribution, however, the segment overall detracted significantly from growth in full year 2024/25, impacted by the voluntary product recall. The impact of the product recall amounted to around DKK 85 million in full year 2024/25, of which around DKK 15 million in Q4.”

Annual report 2025A · The company itself

“The primary packaging is closely tied to their clinical performance, offering essential functionalities like usability and sterility. This connection makes packaging innovation complex in the medical device industry.”

Annual report 2025A · The company itself

“With the wound & tissue repair business, Coloplast is combining advanced wound dressings and Kerecis biologics to create a more comprehensive and clinically differentiated offering within Wound & Tissue Repair. The business is built on Coloplast’s established infrastructure and reputation in Europe and Emerging Markets, complemented by Kerecis’ innovation engine and robust US footprint.”

Annual report 2025A · The company itself

“Over the Impact4 period, we expect the new Wound & Tissue Repair unit to deliver around double-digit organic revenue growth and profitability improvement, underpinned by disciplined execution, clinical evidence, and a strong innovation engine.”

Annual report 2025A · The company itself

“In Women’s Health the strategy centers on transformation through the anticipated launch of Intibia™ in 2026/27, pending FDA approval. Intibia is designed to offer a minimally invasive, durable therapy for overactive bladder, expanding third-line treatment options.”

Annual report 2025A · The company itself

“Growth in this segment is supported by the thulium fiber laser, Coloplast TFL Drive and a disciplined approach to portfolio management.”

Annual report 2025A · The company itself

“In managing material impacts on product quality and safety, direct engagement with consumers and endusers is not the primary focus of our quality processes. However, their perspectives shape health and safety management in post-market surveillance and clinical evaluation studies.”

Annual report 2025A · The company itself

“For all market-released products, we conduct usability studies and clinical evaluations on safety and usage with test populations reflecting our consumers and end-users. These inform design corrections as needed.”

Annual report 2025A · The company itself

“Coloplast's post-market surveillance (PMS) ensures medical device safety and quality throughout its lifecycle. It involves collecting and analysing data on performance, quality, and safety from complaints, clinical data, and market feedback.”

Annual report 2025A · The company itself

“Through quality control, we take proactive measures to prevent negative safety impacts on consumers and end-users, ensuring products meet global safety and performance standards. The quality controls cover our downstream activities globally.”

Annual report 2025A · The company itself

“We take appropriate measures to limit the use of animal testing and discomfort. Therefore, we have a Global Animal Testing Policy dedicated to ensuring commitment to conduct business ethically and with the highest integrity in all its operations.”

Annual report 2025A · The company itself

“Wound & Tissue Repair includes three businesses: advanced dressings, biologics and contract manufacturing. Advanced dressings are the largest business, accounting for around 55% of the total Wound & Tissue Repair sales, while biologics is the second largest business, accounting for around 35% of sales. The remaining 10% of sales are derived from the contract manufacturing of plasters for blisters and cold sores.”

Annual report 2025A · The company itself

“Our portfolio consists of the brands Biatain® Silicone, an advanced foam dressing with a 3DFit Technology, Biatain Superabsorber, Biatain Fiber, Biatain and Comfeel®.”

Annual report 2025A · The company itself

“Most xenografts are derived from porcine or bovine skin, while Kerecis is the only company that markets products based on fish-skin. The patented fish-skin technology that Kerecis has developed is gently processed, clinically differentiated, sustainable, and scalable. The absence of viral disease transmission risk from cold water fish to humans allows for gent processing preserving and the natural structure and components of the skin, with natural elements such as proteins, elastin, glycans and lipid structures remaining intact. This results in a product that is highly similar to human skin, which is a key enabler of improved wound and tissue healing and documented by a compelling body of clinical evidence.”

Annual report 2025A · The company itself

“Titan® Touch, an inflatable penile implant for the management of erectile dysfunction.”

Annual report 2025A · The company itself

“In Women’s Health, Coloplast markets vaginal slings, used to restore continence, and synthetic mesh products, used to treat a weak pelvic floor. Key brands within this segment are Altis® and Restorelle®.”

Annual report 2025A · The company itself

“Within Kidney & Bladder Health, Coloplast offers solutions for kidney stone disease, bladder drainage, voiding dysfunction and prostate disorders. Solutions include flagship brands that provide capital equipment and a comprehensive portfolio of single-use devices.”

Annual report 2025A · The company itself

“In 2022, Coloplast launched its first laser equipment, the thulium fiber laser, Coloplast TFL Drive, for the surgical treatment of kidney stones via ureteroscopy.”

Annual report 2025A · The company itself

“In 2026/27, we expect to enter a fourth segment - the overactive bladder (OAB) segment - with the launch of Intibia™, our implantable tibial nerve stimulator, an Investigational device currently under development with premarket approval submission to the FDA expected in 2025/26. Our anticipated entry into the overactive bladder market will significantly increase the addressable market. The market for third-line therapies for overactive bladder is estimated at around USD 1 billion, with high single-digit growth.”

Annual report 2025A · The company itself

“Revenue from Kerecis amounted to DKK 1,254 million in full year 2024/25, with organic growth of 24%. Growth was broad-based, with continued market share gains and solid contributions across settings.”

Annual report 2025A · The company itself

“In the DMA, and in the context of our products and waste, we considered Ostomy Care, Interventional Urology, Continence Care, Voice & Respiratory Care, and Wound & Tissue Repair as the business areas associated with the impacts and risks.”

Annual report 2025A · The company itself

“Running from February 2024 to June 2025, the SpeediCath Short project sought to launch a shorter version of the SpeediCath® Standard female catheter. The project aimed to launch a product using less material compared to the SpeediCath Standard product range.”

Annual report 2025A · The company itself

“Material reduction and promoting circularity with Luja TM female Luja female is the first and only female intermittent catheter with Micro-hole Zone Technology, enabling complete bladder emptying in one free flow and reducing the risk of urinary tract infections.”

Annual report 2025A · The company itself

“The integration of Atos Medical is progressing according to plan and will be finalised in 2025/26. geographical revenue split 65% 24% 11% 2.3 bn Reported revenue in DKK for 2024/25 % % Reported growth in DKK Reported revenue included a negative effect from FX rates HyperlinkHy perlinkHyper linkHyperlink Hyperlink An introduction to Acute Care Acute Care commercial model Acute Care is our newly formed business unit, which includes Wound & Tissue Repair and Interventional Urology. In Acute Care, we serve patients with acute or temporary conditions within treatment areas characterised by premium products, in Interventional Urology within Men and Womens health with products such as Coloplast’s penile implants and the to be launched Intibia™ for stress urinary incontinence, the Kerecis fish-skin portfolio, and our wound dressings.”

Annual report 2025A · The company itself

“Coloplast is present in three segments of the Interventional Urology market: Men’s Health, Women’s Health, and Kidney & Bladder Health.”

Annual report 2025A · The company itself

“Varje år säljs cirka 280 000 ultraljudssystem, och marknaden förväntas växa med 3,4 % årligen fram till 2028.”

Annual report 2024A · The company itself

“ContextVision är ett ledande mjukvaruföretag med specialistkompetens inom bildanalys och artificiell intelligens, med huvudkontor i Stockholm och grundat 1983. Vi är dedikerade till att leverera bildkvalitet i världsklass och är en betrodd partner till några av världens främsta tillverkare (OEM) av ultraljuds-, röntgen- och MR-utrustning.”

Annual report 2024A · The company itself

“Driva lönsam tillväxt inom Image Quality Vårt mål är att expandera Image Quality-verksamheten genom att optimera hela bildkedjan, och därmed gå bortom traditionella efterbehandlingsmetoder. Med vår expertis inom bildkvalitet kommer vi att utveckla bredare och mer innovativa lösningar för att möta kundernas behov i olika steg av bildhanteringsprocessen.”

Annual report 2024A · The company itself

“Ultraljud står för den största delen av våra intäkter, följt av röntgen, tjänster och MR. Denna fördelning speglar vårt starka fokus på ultraljudslösningar, samtidigt som vi erbjuder ett brett utbud av andra bildbehandlingslösningar och professionella tjänster.”

Annual report 2024A · The company itself

“Affärs- och intäktsöversikt: Ultraljud är fortsatt ContextVisions största affärsområde och står för 65 % av vår totala omsättning.”

Annual report 2024A · The company itself

“ContextVision är den ledande oberoende leverantören inom ultraljudsbildbehandling, en marknad som är en del av den globala ultraljudsindustrin värd 7,5 miljarder USD.”

Annual report 2024A · The company itself

“ContextVisions produktplattform Altumira har funktioner för spridningskorrigering och förbättrar röntgenavbildning genom att möjliggöra minskad stråldos samtidigt som bildkvaliteten förbättras. Denna teknik hanterar den kritiska balansen mellan att minimera patientens strålningsexponering och säkerställa högkvalitativ diagnostik. Genom att effektivisera diagnostikprocessen bidrar tekniken till att förbättra patientvården.”

Annual report 2024A · The company itself

“Marknad: Den globala MR-marknaden är värd cirka 3,4 miljarder USD, med en adresserbar marknad på omkring 4 000 enheter per år. Marknaden förväntas växa med en årlig tillväxttakt (CAGR) på 2,4 % fram till 2028, och vi uppskattar vår marknadsandel till strax under 5 % inom vårt adresserbara segment som oberoende leverantör av bildbehandling för MR.”

Annual report 2024A · The company itself

“Om ContextVision | Året i korthet | Investerarcase | Vd-ord | Case: Data Quality | Marknadstrender | Strategi | Affärsmodell | Hållbarhet | Årsredovisning Tjänster Affärs- och intäktsöversikt: Våra tjänster står för 8 % av vår totala omsättning och omfattar implementeringsprojekt, mjukvaruuppdateringar, uppgraderingar och produktsupport. Tjänsterna är utformade för att komplettera våra produkter genom att förbättra bildkvaliteten och kontinuerligt optimera kundupplevelsen i olika faser.”

Annual report 2024A · The company itself

“ContextVision har byggt sin marknadsledande position genom långvariga partnerskap och samarbetar idag med åtta av de tio största tillverkarna av ultraljudssystem. Dessa samarbeten, som i vissa fall sträcker sig över flera decennier, understryker vår förmåga att leverera högkvalitativa bildbehandlingslösningar med konsekvent precision.”

Annual report 2024A · The company itself

“Under året har vi fört avancerade diskussioner med nyckelkunder, inklusive OEMs, om nya möjligheter för gemensamma utvecklingsprojekt och samarbeten. Dessa initiativ är avgörande för att våra teknologier även framöver ska vara djupt integrerade i ekosystemet för medicinsk bildbehandling.”

Annual report 2024A · The company itself

“Vår affärsmodell bygger på långsiktiga partnerskap med OEM-tillverkare, där vi integrerar vår avancerade mjukvara för medicinsk bildbehandling i ultraljuds-, röntgen- och MR-produkter.”

Annual report 2024A · The company itself

“Any prolonged disruption in the operations of our existing manufacturing or distribution facilities or our fertility and stem cell storage facilities, whether due to work stoppages, technical or labor difficulties, integration difficulties, destruction of or damage to any facility (as a result of natural disaster, use and storage of hazardous materials or other events), enforcement action by the FDA or other regulatory body if we are found to be in non-compliance with current cGMP, QSR or similar foreign requirements or other reasons, could have a material adverse effect on our business.”

Annual report 2025A · The company itself

“We manufacture a significant portion of the medical device products we sell.”

Annual report 2025A · The company itself

“Coverage and Reimbursement Market acceptance and sales of our CooperSurgical products to our customers, who primarily consist of hospitals and surgery centers, OB/GYN medical offices and fertility clinics, will depend on the availability of payor coverage and the adequacy of reimbursement, for the procedures using our products, by government insurance programs and other third-party payors.”

Annual report 2025A · The company itself

“In the United States, we provide donor egg and sperm for fertility treatments, in addition to fertility cryopreservation services and newborn stem cell storage (cord blood and cord tissue).”

Annual report 2025A · The company itself

“The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs and Medicaid health care management services.”

Annual report 2025A · The company itself

“Cordavis The Company launched Cordavis, a wholly-owned subsidiary that works directly with pharmaceutical manufacturers to commercialize and/or co-produce high quality biosimilar products. Through Cordavis, the Company intends to develop a portfolio of products that will provide broader access to biosimilars in the U.S.”

Annual report 2025A · The company itself

“REVENUE IN 2025 2,406 DKK MILLION”

Annual report 2025A · The company itself

“Acquisitions On August 1, 2023, the Company completed the acquisition of Spectrum Plastics Group ("Spectrum") from AEA Investors. Spectrum is a recognized leader in the advanced manufacturing of specialty medical devices and components with a strategic focus on key therapeutic areas such as structural heart, electrophysiology, surgical robotics and cardiovascular.”

Annual report 2025A · The company itself

“Details on Healthcare & Water Technologies' 2025 net sales, by business and geographic region, are as follows: Healthcare Technologies delivers specialized materials and product design, prototyping, and manufacturing services tailored for situations where technological advancement is paramount, and the assurance of quality and performance is required. This business produces medical packaging, high-performance parts and components to meet stringent performance, quality, and regulatory requirements for the biopharma and medical device markets. Key offerings include specialty components for medical devices, TYVEK® medical packaging and garments, as well as TYCHEM® protective suits.”

Annual report 2025A · The company itself

“Healthcare & Water Technologies is a global leader in providing innovative high-performance products, components, and solutions across a number of industries including medical packaging, medical devices, water filtration and purification, and protective garments.”

Annual report 2025A · The company itself

“ Detta är Dynavox Group Värdeskapande Erbjudande Hållbarhet Årsredovisning Innehåll Dynavox Group tillhandahåller hållbara, heltäckande kommunikationslösningar för personer med kommunikationsnedsättningar.”

Annual report 2024A · The company itself

“Vi är den globala leverantören av heltäckande lösningar för kommunikationshjälpmedel.”

Annual report 2024A · The company itself

“Rehadapts monteringslösningar kan fästas på rullstolar, sängar, skrivbord, fåtöljer eller var som helst där en användare av kommunikationshjälpmedel behöver komma åt sin enhet. Sedan Rehadapt grundades för nästan tjugofem år sedan har företaget byggt upp ett gott rykte för kvaliteten på sina monteringslösningar. Från sin produktionsanläggning i Kassel i Tyskland levererar Rehadapt till leverantörer av kommunikationshjälpmedel över hela världen.”

Annual report 2024A · The company itself

“Life Sciences is comprised of customers and accounts related to manufacturing in the following industries: pharmaceutical, animal health and medicine, blood purification and dialysis, biologic products, cosmetics and medical devices.”

Annual report 2025A · The company itself

“Organic sales for Global Life Sciences increased 5% in 2025 as compared to 2024 driven by new business wins and progressively improving industry trends.”

Annual report 2025A · The company itself

“Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively.”

Annual report 2025A · The company itself

“Sales of our TMTT products represented 9%, 7%, and 4% of our net sales in 2025, 2024, and 2023, respectively.”

Annual report 2025A · The company itself

“Table of Contents Sales of our surgical tissue heart valve products represented 17%, 18%, and 19% of our net sales in 2025, 2024, and 2023, respectively.”

Annual report 2025A · The company itself

“Today, Elanders are experts within medical logistics with a global footprint, committed to delivering services at the highest level of quality without compromise and with continuous improvements. The clients are efficiently supported throughout the product life cycle, starting from the procurement of materials, through manufacturing and assembly, as well as distribution, and on to aftermarket services and the handling of equipment that is worn-out. Elanders can manage entire logistics chains and ensure that end customers are provided with the equipment, spare parts and consumables, at the right time.”

Annual report 2024A · The company itself

“The Group handles all aspects of logistics and transport, as well as providing and coordinating value-added services for sensitive health care equipment and in vitro diagnostics (IVD). This includes demo pool services, installation services, taking back wornout equipment, as well as temperature-controlled storage in different climate zones down to –80 degrees Celsius.”

Annual report 2024A · The company itself

“The company is a partner to some of the world’s leading companies in consumer electronics, communications, computing, medical technology, software and retail.”

Annual report 2024A · The company itself

“That said, we see strong potential to extend cycle life further to meet future needs, particularly in next-generation medical devices. A sector with evolving and stringent demands.”

Annual report 2024A · The company itself

“Our continued dialogue with the market consistently affirmsourleadershipposition. At the MedTech conference in Los Angeles in February2025,weshowcasedourtechnologytoa highly regulated and demanding audience. MedTech companies require batteries with superior energy density, longer cycle life, and absolute safety, are areas where we have a clear competitive edge in performance, cost, and speed of development.”

Annual report 2024A · The company itself

“Kliniska studier är av stor betydelse inom området för reparation av broskskador i leder. Samarbetet med olika läkare och kliniker är väldigt viktigt för Episurf Medicals verksamhet.”

Annual report 2024A · The company itself

“Bolaget arbetar med fortsatt produktutveckling för att möta marknadens efterfrågan.”

Annual report 2024A · The company itself

“DETTA ÄR EPISURF MEDICAL – en unik lösning för varje patient EPISURF MEDICAL GRUNDADES 2009 och erbjuder människor med smärtsamma ledskador ett aktivare och friskare liv genom skräddarsydda behandlingsalternativ. Vi sätter patienten i centrum för design av implantat och kirurgiska instrument. Genom att kombinera avancerad 3D-bildteknik med de senaste tillverkningsteknikerna anpassar vi inte bara varje implantat utan även de kirurgiska instrumenten till patientens unika skada och anatomi.”

Annual report 2024A · The company itself

“Episurf Medical har två av implantatsystem för knäleden » Episealer® Knee (innefattar Episealer® Condyle Solo, Episealer® Trochlea Solo och Episealer® Femoral Twin) för behandling av avgränsade brosk- och benskador på femursidan (lårbenssidan) i knäleden » Episealer® Patellofemoral System för behandling av artros i patellofemorala delen av knäleden Episurf Medical har ett implantat för fotleden » Episealer® Talus för behandling av brosk- och benskador på språngbenet (talus) i fotleden Produktutveckling » Episurf Medical har, förutom kontinuerliga förbättringar av existerande produkter, för tillfället en produkt i produktutvecklingsstadiet; ett implantat för den så kallade MTPleden i stortån.”

Annual report 2024A · The company itself

“Episurf Medical är ett medicintekniskt bolag som utvecklar och kommersialiserar patientunika produkter för behandling av smärtsamma ledskador. Genom att kombinera expertis inom implantatutveckling med patenterad teknologi för individanpassad design och produktion kan Episurf Medical tillverka perfekt avpassade implantat utifrån varje enskild patients unika anatomi och skada i syfte att ge människor med smärtsamma ledskador ett aktivare och friskare liv.”

Annual report 2024A · The company itself

“Episurf Medicals första implantatsprodukter Episealer® Condyle Solo, Episealer® Trochlea Solo och Episealer® Femoral Twin erhöll CE-märkning under 2013, 2014 respektive 2015. Dessa knäimplantat, vanligtvis benämnda Episealer® Knee, är de första individanpassade ytersättningsimplantaten i världen för behandling av broskskador i knäleden.”

Annual report 2024A · The company itself

“I december 2022 erhölls bolagets första marknadsgodkännande för USA genom godkännandet från FDA (U.S. Food and Drug Administration) för Episealer® Patellofemoral System. Systemet är baserat på teknologin för Episealer® Trochlea Solo and Episealer® Femoral Twin, med tillägget av ett andra implantat för behandling av skada på baksidan av knäskålen (patella). Detta system utgör inte bara bolagets första produkt på USA-marknaden, men också en ny produkt utvecklad för en bredare indikation, då det är Episurf Medicals första produkt för behandling av artros.”

Annual report 2024A · The company itself

“Bolaget har fortsatt utvecklingsarbetet kring ett individanpassat implantat och tillhörande kirurgiska instrument för behandling av artros i den så kallade MTP-leden i stortån under 2024. Detta är ett nytt implantat som är baserat på Episurfs patenterade implantatteknologi.”

Annual report 2024A · The company itself

“Vårt starkaste bidrag är att erbjuda människor med smärtsamma ledskador ett längre, aktivare samt friskare liv genom att tillgängliggöra effektiva, minimalt invasiva skräddarsydda behandlingsalternativ.”

Annual report 2024A · The company itself

“EQT behöll sitt ägande och utnyttjade den ökade likviditeten från börsnoteringen, vilket skapade möjligheter för framtida avyttringar. Vid slutet av 2024 hade börsintroduktionen genererat en avkastning på 90 % för de investerare som deltog vid börsintroduktionen.”

Annual report 2024A · The company itself

“#01 Detta är EQT #02 Finansiella rapporter #03 Hållbarhetsnoter #04 Bolagsstyrning #05 Ytterligare information Hälsovård — MedTech — Life Science-verktyg och diagnostik — Läkemedel och relaterade tjänster — Hälsovårds-IT Tjänster — Outsourcing av kritiska tjänster — Nätverkstjänster — Tekniktjänster Teknologi — Mjukvara — Konsumentinriktade internettjänster — Digitala medier och underhållning Industriell teknologi — Automatisering och Internet of Things — Hållbarhetsteknik — Livsmedelsteknik 41% 31% 5% 23% 2% 27% 16% 15% 8% 32% Klimat & Natur Hälsa & Välmående Tillgång & Jämlikhet Motståndskraft & Transparens Vår uppkopplade värld Modularisering av teknologi Distribuerat ägande & Decentralisering Hälsovård Teknologi Tjänster Industriell teknologi Tjänster Tekniska tjänster Teknologi Hälsovård Industriell teknologi Annat – EQT Private Capital EQT:s affärssegment Private Capital investerar utifrån en tematisk investeringsstrategi kombinerad med djup sektorexpertis, med fokus på ledande icke-cykliska bolag.”

Annual report 2024A · The company itself

“Terveydenhuolto ja lääkinnälliset laitteet: Turvallisuuskriittiset järjestelmät ja vaatimustenmukaisuusdokumentaatio lääketeknologialle, varmistaen sääntelyvaatimusten täyttymisen.”

Annual report 2025A · The company itself

“•We are subject to complex and evolving trade policies, export controls and sanctions. •Failure to comply with data privacy and cybersecurity laws and regulations could expose us to government enforcement, significant penalties, civil litigation, and reputational harm. •Inadequate protection of our intellectual property and exposure to third-party intellectual property claims could adversely affect our business and results of operations. •Our compliance program may not prevent violations of anti-corruption and related laws, which could result in severe penalties, business restrictions, and reputational harm. •Defects or failures in our products, manufacturing processes, or design and engineering services could expose us to product liability, warranty claims, contractual penalties, and reputational harm. •We may not meet regulatory quality standards applicable to our manufacturing and quality processes for medical devices, which could have an adverse effect on our business, financial condition, and results of operations.”

Annual report 2026A · The company itself

“That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position; •certain of our products are medical devices that are subject to regulation by the U.S. FDA, by other federal and state governmental agencies, by comparable agencies of other countries and regions, and by certain accrediting bodies. To varying degrees, these regulators require us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing, distribution, and post-marketing surveillance of our products.”

Annual report 2025A · The company itself

“Gentian’s expertise and focus lies within immunoassays, specifically for infections, inflammation, kidney disease and congestive heart failure.”

Annual report 2024A · The company itself

“Gentian aims to protect life and improve health by improving diagnostic efficiency and decision making in the clinical setting enabling better treatment. The company develops and manufactures high quality, in vitro diagnostic (IVD) reagents for a wide range of clinical chemistry analysers. The product lines of laboratory tests, for various diagnostic targets, provide high accuracy and fast results for both human and veterinary healthcare.”

Annual report 2024A · The company itself

“Kundbasen är bred och diversifierad inom branscher som energi, medicinteknik, försvarsindustri, jordbruksmaskiner, returautomater och gruvdrift.”

Annual report 2024A · The company itself

“The FDA regulates certain computer software and digital health products intended for use in health care settings, including, for example, AI and machine learning-enabled medical devices and the cybersecurity of medical devices. Certain of our businesses involve the development and sale of software and related products to support physician and dental practice management, and it is possible that the FDA or foreign government authorities could determine that one or more of our products is subject to regulation as a medical device, which could subject our businesses to substantial additional requirements, costs, potential enforcement actions or liabilities for noncompliance with respect to these products. For example, some of our imaging software is regulated as a medical device which subjects our businesses to substantial additional requirements, costs and potential enforcement actions or liabilities for noncompliance with respect to these products.”

Annual report 2025A · The company itself

“In addition, as our corporate brand business continues to grow, purchasers of such products may increasingly seek recourse directly from us, rather than the ultimate product manufacturer, for product-related claims. Another potential risk we face in the distribution of our products is liability resulting from counterfeit or tainted products infiltrating the supply chain.”

Annual report 2025A · The company itself

“We face inherent risk of exposure to product liability, intellectual property infringement and other claims in the event that the use of the products we sell results in injury. Our business involves a risk of product liability, intellectual property infringement and other claims in the ordinary course of business, and from time to time we are named as a defendant in cases as a result of our distribution of products.”

Annual report 2025A · The company itself

“This segment also markets and sells under our own corporate brand, a portfolio of cost-effective, high-quality consumable merchandise; • Global Specialty Products: manufacturing, marketing and sales of dental implant and biomaterial products; endodontic, orthodontic and orthopedic products and other health care-related products and services; and • Global Technology: development and distribution of practice management software, e-services, and other products, which are distributed to health care providers.”

Annual report 2025A · The company itself

“We develop, manufacture, market and distribute a broad portfolio of patented and evidence-based dental implants, prosthetic components, instruments and digital workflow solutions for implant-based tooth restorations. With research and development and manufacturing facilities in the United States, Switzerland, Germany, Brazil and France, we serve customers with various global and regional implant brands across a wide range of price segments.”

Annual report 2025A · The company itself

“As a distributor, we market and sell branded products as well as our own corporate brand portfolio of cost-effective, high-quality consumable merchandise products. We also manufacture, source and sell a range of company-owned manufactured products, primarily implants, biomaterial products, endodontics, handpiece and small equipment, hand instrument and repair, restoratives, orthodontics, wound care, orthopedics and dental lab products.”

Annual report 2025A · The company itself

“Global Specialty Products includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health carerelated products and services.”

Annual report 2025A · The company itself

“Kunderna är i huvudsak den globala fordons- och verkstadsindustrins systemleverantörer, bygg- och anläggningsbranschen och inom sektorer som transport, energi och konsument samt kabelindustrin och tillverkare av medicinteknik, plattvärmeväxlare och truckar.”

Annual report 2024A · The company itself

“HEXPOL:s avancerade polymerlösningar efterfrågas i allt större omfattning för applikationer inom segmentet hälsa & medicinteknik.”

Annual report 2024A · The company itself

“HEXPOL fokuserar på marknader i stark tillväxt med intressanta och växande kund applikationer inom bland annat hälsa & medicin teknik, allmänindustri, konsumentprodukter och fordons industrin.”

Annual report 2024A · The company itself

“Affärsområdet levererar compounds och applikationer till bland annat hälsa & medicin teknik, allmänindustri, konsumentprodukter och fordons industrin, men även till transportsektorn såsom till tåg-, flyg- och rymdindustri.”

Annual report 2024A · The company itself

“Hiab edistää uraauurtavaa innovaatiota asiakaslähtöisillä ratkaisuilla, joissa suorituskyky ja turvallisuus ovat etusijalla. Ratkaisut hyödyntävät liitettävyyttä, datapohjaisia palveluita sekä sähköistymistä ja edistyneitä ohjausjärjestelmiä.”

Annual report 2025A · The company itself

“Human point-of-care electrolyte and blood gas analyzers. Our human point-of-care electrolyte and blood gas analyzers are classified by the FDA as Class I and/or Class II medical devices, and their design, manufacture, and marketing are regulated by the FDA.”

Annual report 2025A · The company itself

“IMAGE SYSTEMS ÅRSREDOVISNING 2024 13 MOTION ANALYSIS - HÖG MÄTPRECISION Motion Analysis är världsledande på att mäta rörelse i höghastighetsfilm. Den mjukvara som utvecklas och säljs används idag i hundratals olika applikationer där våra kunder kräver världens bästa noggrannhet.”

Annual report 2024A · The company itself

“Detta används inom olika områden, som tester av militärutrustning, bilkrocktester och forskning på universitet.”

Annual report 2024A · The company itself

“The acquisition accelerates Incap’s growth strategy by strengthening its position also in defense, railway technology, and medical technology sectors.”

Annual report 2025A · The company itself

“The company manufactures for customers in aerospace, automotive, consumer electronics, data storage and media, defence, green energy, food and vending, industrial controls, automation, medical, oil, gas and mining, power, security, telecom, transport and infrastructure, gaming and other industries.”

Annual report 2025A · The company itself

“Positive Displacement (PD) Pumps Positive displacement pumps are essential to highly specialized flow applications across many industries. We are a market leader in positive displacement pumps, covering the main technology types including diaphragm, vane, piston, progressive cavity, peristaltic and gear.”

Annual report 2025A · The company itself

“Liquid ring vacuum pumps are used for extreme conditions, which prevail in humid and wet processes across ceramics, environmental, medical and plastics applications.”

Annual report 2025A · The company itself

“There have been reports and articles published questioning patient safety and efficacy associated with robotic-assisted surgery with da Vinci surgical systems, their cost relative to other disease management methods, and the adequacy of surgeon training. Negative publicity, including statements made by public officials, whether accurate or inaccurate, concerning our products or our Company could reduce acceptance of our products and could result in decreased product demand and a decline in revenues.”

Annual report 2025A · The company itself

“Our success depends on the quality and reliability of our products. While we subject components sourced and products manufactured to stringent quality specifications and processes, our products incorporate mechanical parts, electrical components, optical components, and computer software, any of which may contain errors or exhibit failures, especially when products are first introduced.”

Annual report 2025A · The company itself

“Products Systems Our robotic-assisted platforms extend the care teams’ capabilities to deliver minimally invasive care. These platforms include da Vinci surgical systems, which are designed to enable a wide range of surgical procedures across a broad patient population using a minimally invasive approach, and the Ion endoluminal system, which extends our commercial offerings beyond surgery into diagnostic procedures, enabling minimally invasive biopsies in the lung.”

Annual report 2025A · The company itself

“Da Vinci Surgical Systems Intuitive launched its first da Vinci surgical system in 1999, with the goals of enhancing surgical capabilities and facilitating less invasive care through improved precision, vision, and control. In 2000, the FDA cleared da Vinci for use in general laparoscopic surgery. Since then, we have received numerous additional indications in the U.S. and in countries around the world, for a broad array of procedures across general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties, among others.”

Annual report 2025A · The company itself

“Ion Endoluminal System In 2019, the FDA cleared our Ion endoluminal system, which is a flexible, robotic-assisted, catheter-based platform that utilizes instruments and accessories for which the first cleared indication is minimally invasive biopsies in the lung. Our Ion system extends our commercial offering beyond surgery into diagnostic, endoluminal procedures.”

Annual report 2025A · The company itself

“Accessory Products. We sell various accessory products, which are used in conjunction with the da Vinci surgical systems. Accessory products include sterile drapes used to help ensure a sterile field during surgery, vision products, such as replacement 3D stereo endoscopes, camera heads, and light guides, and other items that facilitate the use of the da Vinci surgical systems.”

Annual report 2025A · The company itself

“Ion Instruments. Instruments utilized with our Ion system include our fully articulating catheter, which is employed to navigate the intricate and narrow airways of the lungs, our peripheral vision probe, an endoscope that provides real-time airway visualization for catheter navigation, and our Flexision biopsy needles, which are used to procure tissue samples from lung nodules.”

Annual report 2025A · The company itself

“Services We have a network of field service engineers across the U.S., Canada, Europe, and Asia and maintain relationships with various distributors around the globe. This infrastructure of customer service and support specialists offers a full complement of services, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring.”

Annual report 2025A · The company itself

“Perioperative Consulting. We offer a suite of customized solutions to improve a hospital’s efficiency and performance with Intuitive technologies.”

Annual report 2025A · The company itself

“Our Custom Hospital Analytics program enables the integration of data sources so that individual health institutions can analyze their data in their own environment. Using this data, hospital and healthcare system executives, administrators, care teams, and surgeons can gain alignment around their programs based on their KPIs, determine best practices, assess gaps, and develop and implement actionable steps to address any gaps.”

Annual report 2025A · The company itself

“3D Modeling Services. Intuitive 3D Models is our augmented reality imaging product for use in kidney, prostate, lung, and rectal procedures.”

Annual report 2025A · The company itself

“The da Vinci surgical systems, Ion endoluminal system, and many of our other products represent a novel and advanced approach to performing medical procedures. Achieving and maintaining physician, patient, and third-party payor acceptance of robotic-assisted medical procedures as a preferred method of performing these procedures is crucial to our success. If our products fail to achieve or maintain customer acceptance, customers will not purchase our products, and we will not be able to generate the revenue necessary to support our business.”

Annual report 2025A · The company itself

“Den totala köpeskillingen uppgick till 165MUSD.”

Annual report 2022A · The company itself

“Anställda utbildade i antikorruption och mutor, % Olycksfallsfrekvens 0,61 0,98 Upplevd grad av inkludering bland medarbetare, skala 1-5 3,8 n/a Könsfördelning bland chefer, andel kvinnor % En leverantör av produkter för diagnostik och behandling inom urologi och urogynekologi, gastroenterologi, samt obstetrik, gynekologi och neonatalvård. www.laborie.com • Som industriledande innovatör har Laborie betydande långsiktig tillväxtpotential, driven av gynnsamma underliggande demografiska trender, fortsatta investeringar i produktutveckling och global expansion, samtett flertal möjligheter till strategiska förvärv. • Laborie bör fortsätta att fokusera på att accelerera investeringar i utveckling och lansering av innovativa produkter, inklusive Optilume™ och Eclipse™, expandera globalt på nya marknader och på att utvärdera strategiska investeringar och förvärv inom både befintliga och nya behandlingsområden. *Total exponering: 98% BEDÖMT VÄRDE, RAPPORTERAD EBITATILLVÄXT CO LEDNINGSGRUPP, KVINNOR mdr    –  Sarnova • Den organiska omsättningstillväxten uppgick till 2 procent i konstant valuta.”

Annual report 2022A · The company itself

“Business Our Company IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries.”

Annual report 2025A · The company itself

“Our insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.”

Annual report 2025A · The company itself

“Our Clients Sales to companies in life sciences, including pharmaceutical companies, biotechnology companies, device and diagnostic companies, and consumer health companies, account for the majority of our revenues.”

Annual report 2025A · The company itself

“We partner with biopharmaceutical companies and other life sciences providers (e.g., medical device companies) to develop and deploy tailored stakeholder engagement solutions, including contract sales and market access professionals, which are focused on product sales and improving brand value at all stages of the product lifecycle from initial market entry to brands nearing patent expiry.”

Annual report 2025A · The company itself

“Pii is a contract development and manufacturing organization specializing in early stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing. The acquisition is expected to enhance the Company’s existing Regulated Industries service offerings, which includes the development and commercial production of auto-injectors, pen injectors, inhalers, and on-body pumps.”

Annual report 2025A · The company itself

“Tillsammans representerar dessa en global marknadsmöjlighet för bolaget som år 2025 förväntas vara värd USD 600–800 miljoner.”

Annual report 2024A · The company itself

“Identifiering av projekt som kan innebära stora medicinska genombrott Karolinska Development är ett investmentbolag som fokuserar på att identifiera och investera i lovande medicinska innovationer genom att handplocka forskningsbolag och utvecklingsprojekt från Karolinska Institutet och andra välrenommerade universitet och forskningsinstitutioner i Norden. Bolaget investerar i läkemedelsprojekt och medicintekniska produkter med potential att revolutionera behandlingen av sjukdomar där behovet av nya terapier är stort.”

Annual report 2024A · The company itself

“Vid engagemang i medicintekniska företag är affärsmodellen att finansiera bolagen till dess att bolagen uppvisar ett positivt rörelseresultat.”

Annual report 2024A · The company itself

“Våra noterade innehav OssDsign och Promimic fortsätter att utvecklas väldigt positivt. Båda bolagen, som fokuserar på att marknadsföra sina medicintekniska produkter på den amerikanska marknaden, rapporterar försäljningstillväxt redan i detta tidiga skede av sina kommersiella resor.”

Annual report 2024A · The company itself

“Diversifierad och balanserad portfölj Investeringsportföljen består i dag av elva bolag med delvis olika profil och mognadsgrad – där flera läkemedelsprojekt befinner sig i sen klinisk utvecklingsfas och våra medicintekniska bolag redan befinner sig i kommersialiseringsfas.”

Annual report 2024A · The company itself

“Promimic (Göteborg, Sverige) är företaget bakom HA nano Surface, en ytbehandling som idag används kliniskt på omkring 2,0 miljoner implantat. HA nano Surface är en nanometertunn beläggning av hydroxylapatitkristaller som stimulerar tillväxten av benceller.”

Annual report 2024A · The company itself

“OssDsign (Uppsala, Sverige) utvecklar och kommersialiserar nästa generations benersättningsprodukter.”

Annual report 2024A · The company itself

“Kitron’s Connectivity sector is focused on connected devices. Many of these devices are sensors, continuously feeding data into increasingly advanced software, utilizing artificial intelligence to make predictions and improve efficiency and safety. Examples are multiplying, in everything from industrial control systems to medical devices monitoring vital functions and modern cars, containing many sensors communicating with the Internet.”

Annual report 2024A · The company itself

“The medical device sector consists of the product areas diagnostics, life support, surgical, hospital and home care. Kitron is especially strong in ultrasound and cardiology systems, respiratory medical devices and Lab/IVD (In-Vitro Diagnostics).”

Annual report 2024A · The company itself

“Lifco har definierat hållbarhetsrelaterade produkter och tjänster som sådana där till exempel arbetsmiljöförbättringar, positiva miljöeffekter eller energieffektivitet och minskad energiförbrukning är tydliga konkurrensfördelar eller där produkterna ingår i cirkulära affärsmodeller. Vid beräkningen har Lifco inkluderat dentalverksamheten, rivningsrobotar, divisionen miljöteknik, verksamheten inom division kontraktstillverkning som avser produktion av medicintekniska produkter samt bolaget Cramaro Tarpaulin i divisionen service och distribution.”

Annual report 2024A · The company itself

“Nettoomsättning per medarbetare 3,72 -5,1% 3,92 10,7% 3,54 Rivningsrobotar Verktyg till grävmaskiner och kranar Övriga nischmaskiner 19% 24% 57% 12% 13% 10% 28% 17% 13% 2% 5% Sverige Tyskland Italien Storbritannien Nordamerika Innehållsförteckning VD-kommentar Förvärvsprocess Aktien Dental Kontraktstillverkning De svenska bolagen Leab, Texor och Zetterströms Rostfria utför kontraktstillverkning av produkter för olika branscher, bland annat verkstadsindustrin och medicinteknik. Bolagen fokuserar på tillverkning av produkter där kraven på kvalitet och leveransservice är höga och där tillverkningen är en viktig del i produktens värdekedja.”

Annual report 2024A · The company itself

“To support this, we have partnered with TTP plc (The Technology Partnership), a global expert in medical implants and sensors. This collaboration will help us refine our prototype, improving Successful Sencell pilot production Chemistry breakthrough improved glucose sensitivity Read more Read more both product performance and production efficiency.”

Annual report 2024A · The company itself

“We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products.”

Annual report 2025A · The company itself

“We sell and provide services involving complex software and technology that may contain errors, especially when first introduced to market. Healthcare professionals delivering patient care have heightened sensitivity to system and software errors due, among other reasons, to the critical nature of healthcare decisions.”

Annual report 2026A · The company itself

“Our Oncology & Multispecialty segment includes provider solutions that encompass specialty drug distribution, group purchasing organizations, infusion services, direct to patient pharmacy capabilities, InspiroGene™ cell and gene therapy services, technology solutions, practice consulting services, and vaccine distribution.”

Annual report 2026A · The company itself

“Our Medical-Surgical Solutions segment is a leading provider of medical-surgical supplies, laboratory equipment, and pharmaceutical distribution, logistics, and other services to non-acute settings in the U.S.”

Annual report 2026A · The company itself

“•Prescription Technology Solutions segment combines automation and our ability to navigate the healthcare ecosystem to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address patients’ medication access, affordability, and adherence challenges.”

Annual report 2026A · The company itself

“Affärsområdet Hjälpmedel som etablerades förra året utvecklades mycket starkt. Bolagen inom affärsområdet gjorde operationella framsteg och uppvisade både organisk omsättnings- och resultattillväxt.”

Annual report 2024A · The company itself

“Affärsområdet Hjälpmedel innehåller de rörelsedrivande bolagen Abilia, Erimed, Huka, Swedelift och Trident.”

Annual report 2024A · The company itself

“Affärsområdet Medicinteknik innehåller de rörelsedrivande bolagen Cardiolex, Inpac, Multi-Ply och Toul Meditech.”

Annual report 2024A · The company itself

“Medicintekniskt klassad utrustning och förbrukningsvaror som genererar ultrarena luftflöden för operationsmiljöer, i syfte att minska risken för kontaminering och därmed postoperativa infektioner. Huvudsakliga produktområden: Operio och SurgiCube.”

Annual report 2024A · The company itself

“Koncernen tillverkar och säljer läkemedel samt medicin teknisk utrustning i form av EKG -utrustning, radiologiutrustning, renluftsaggregat och hjälpmedel för personer med funktionsnedsättningar.”

Annual report 2024A · The company itself

“Table of Contents CARDIOVASCULAR PORTFOLIO The Cardiovascular Portfolio is made up of the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular divisions. The primary medical specialists who use our Cardiovascular products include electrophysiologists, implanting cardiologists, heart failure specialists, cardiovascular, cardiothoracic, and vascular surgeons, and interventional cardiologists and radiologists. Cardiac Rhythm & Heart Failure Our Cardiac Rhythm & Heart Failure division includes the following Operating Units: Cardiac Rhythm Management and Cardiac Ablation Solutions. The division develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure.”

Annual report 2026A · The company itself

“NEUROSCIENCE PORTFOLIO The Neuroscience Portfolio is made up of the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. The primary medical specialists who use the products of this group include spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, interventional radiologists, and ear, nose, and throat specialists.”

Annual report 2026A · The company itself

“MEDICAL SURGICAL PORTFOLIO The Medical Surgical Portfolio includes the Surgical & Endoscopy and Acute Care & Monitoring divisions. Products and therapies of this group are used primarily by healthcare systems, physicians' offices, ambulatory surgical centers (ASCs), and other alternate site healthcare providers.”

Annual report 2026A · The company itself

“We compete in both the therapeutic and diagnostic medical markets in more than 150 countries throughout the world. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our product lines face a mix of competitors ranging from large companies with multiple business lines to small, specialized manufacturers that offer a limited selection of niche products.”

Annual report 2026A · The company itself

“We manufacture the majority of our products and procure critical third-party services, such as sterilization services, at numerous facilities worldwide.”

Annual report 2026A · The company itself

“In addition, many of our products require sterilization before sale and several of our key products are manufactured or sterilized at a particular facility, with constrained capacity and limited options for alternate sterilization facilities.”

Annual report 2026A · The company itself

“Our Mission is to provide a broad range of therapies to restore patients to fuller, healthier lives, which requires a wide variety of technologies, products and capabilities.”

Annual report 2026A · The company itself

“Our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices. In addition, many of our products are often used in intensive care settings with seriously ill patients, and some of the medical devices we manufacture and sell are designed to be implanted in the human body for long periods of time or indefinitely.”

Annual report 2026A · The company itself

“Hospital Acute Care Bridion (sugammadex), a medication for the reversal of two types of neuromuscular blocking agents used during surgery; Prevymis (letermovir) for the prophylaxis of cytomegalovirus (CMV) infection and disease, or of CMV disease, in certain high risk adult and pediatric recipients of an allogeneic hematopoietic stem cell transplant or of a kidney transplant, respectively; Zerbaxa (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections; and Dificid (fidaxomicin) for the treatment of C. difficile-associated diarrhea.”

Annual report 2025A · The company itself

“The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions.”

Annual report 2025A · The company itself

“Further, we sell to customers in industries such as automotive, aerospace, defense, safety, security, and medical, where failure of the application could cause damage to property or persons.”

Annual report 2026A · The company itself

“In addition, if our products and solutions perform critical functions in our customers’ products or are used in high-risk consumer end products, such as autonomous driver assistance programs, home and enterprise security, smoke and noxious gas detectors, medical monitoring equipment, or wearables for child and elderly safety, our potential liability may increase.”

Annual report 2025A · The company itself

“Att bolaget missar viktiga steg i den biomekaniska utvecklingen inom hjälmsäkerhet Utvecklingen inom hjälmsäkerhet och rotationsrörelser förändras över tid och ett flertal organ arbetar med att uppdatera sina standarder inom hjälmtestning för att även kunna inkludera rotationsrörelser i certifiering av hjälmar. Konsekvensen av en annorlunda standard än den som Mips representerar skulle kunna få en negativ påverkan på Mips försäljning inom de kategorier som en sådan standard avser.”

Annual report 2024A · The company itself

“Mips patenterade säkerhetssystem kan integreras i en mängd olika typer av hjälmar för både konsumenter (t ex cykel-, snö-, motorcykel-, rid- och lagsportshjälmar) och professionella användare (t ex industri-, militär-, polis-, sök- och räddningshjälmar).”

Annual report 2024A · The company itself

“Med MOB-015 (Terclara ® ) som ankare avser bolaget att utöka produktportföljen med ytterligare förvärvade produkter inom närliggande områden.”

Annual report 2024A · The company itself

“Moberg på 2 min Moberg Pharma är ett specialistläkemedelsbolag inom dermatologi med fokus på kommersialisering av egenutvecklade läkemedel baserade på innovativa beprövade substanser.”

Annual report 2024A · The company itself

“Vi har även kunder i branscher som flygteknik, försvar, fordonsindustri, datakommunikation, medicin, energi, järnväg, säkerhetskritiska sektorer och telekom.”

Annual report 2024A · The company itself

“Kunderna är främst aktiva inom industrisegmentet, försvarsindustrin samt inom medicinteknik och elbilsladdare.”

Annual report 2024A · The company itself

“Vår verksamhet i USA är uppbyggd av ett antal förvärv och kunderna är främst verksamma inom industri och medicinteknik.”

Annual report 2024A · The company itself

“- Another important development during 2024 was securing NEXT’s first design-win in the touchpad sector.”

Annual report 2024A · The company itself

“NEXT Biometrics at a glance NEXT provides advanced fingerprint sensor technology that delivers uncompromised security and accuracy for the best possible user experience in the banking & finance, government ID, access control and laptop & notebook market areas.”

Annual report 2024A · The company itself

“The customer’s end-user product is a medical keyboard aimed at industrial use, with NEXT supplying the customer with fingerprint modules and touchpads for the keyboard.”

Annual report 2024A · The company itself

“BIDRAR TILL MINSKADE UTSLÄPP AV VÄXTHUSGASER Hög utvecklingstakt på utrustning som räddar liv Inom den medicintekniska industrin går utvecklingen snabbt framåt och nya lösningar räddar liv. NIBE Groups dotterbolag bidrar med att ligga i framkant vadgällerutveckling avprodukterbaserade på folieelement förolika applikationer, exempelvis operationsbord, steriliseringsutrustning, DNA-analyser och respiratorer.  Nyamodelleravhybridfordonlanseraskontinuerligtförsåvälpersontrafiksom för fordon avsedda för kommersiellt bruk. Vi deltar aktivt i utvecklingen av produkterföreffektivtenergiutnyttjandeochlevererarexempelviselementför batterivärmareochkupévärmaregenomattblandannatutnyttjabromsenergin.”

Annual report 2024A · The company itself

“Nolato är en globalt etablerad utvecklings- och produktionspartner till ledande företag Nolato är en global koncern som utvecklar och tillverkar produkter främst i polymera material som plast, silikon och termoplastiska elastomerer (TPE). Koncernen arbetar nära kunder med ledande position inom områden som medicinteknik, läkemedel, konsumentelektronik, telekom, fordon, hygien och andra utvalda industriella områden.”

Annual report 2024A · The company itself

“Ett värdefullt hjälpmedel för matallergiker Det amerikanska företaget Amulet Inc. har utvecklat en produkt som kombinerar avancerad teknik med användarvänlighet och som ger bättre insyn i vad maten innehåller. Produkten Allergy Amulet är en liten, diskret och snabb allergisensor, som kan bäras som ett smycke runt halsen.”

Annual report 2024A · The company itself

“Affärsområdet Medical Solutions är verksamt på marknaden för medicinteknisk utrustning, läkemedelsindustri samt diagnostik med utveckling och tillverkning av komplexa produktsystem och komponenter med bas i avancerad polymerteknologi och automation.”

Annual report 2024A · The company itself

“Huvuddelen av det som produceras är olika typer av plastbaserade kirurgiska verktyg och instrument av engångskaraktär, som används vid operation eller för undersökningar.”

Annual report 2024A · The company itself

“Diagnostik var det starkast växande marknadsområdet inom affärsområdet, där Medical Solutions producerar engångsmaterial för diagnostiktester såsom pipetter, och provrörskoppar.”

Annual report 2024A · The company itself

“Endoskopi och allmän kirurgi 22% (23) In-vitrodiagnostik Drug delivery 16% (14) Läkemedelsförpackningar MEDICAL SOLUTIONS AFFÄRSOMRÅDEN Rörelseresultat (EBITA), MSEK EBITA-marginal, % Nettoomsättning, MSEK Affärsområdets enheter Investeringar, MSEK Kassaflödespåverkande, exklusive rörelseförvärv och avyttringar Kassaflöde, MSEK Avkastning, % Operativt kassaflöde efter inv.verksamh. exkl förv. & avyttr.”

Annual report 2024A · The company itself

“Automatmontering görs framförallt av medicintekniska hjälpmedel, exempelvis autoinjektorer som monteras automatiskt i höga volymer.”

Annual report 2024A · The company itself

“Bolagen i koncernen utvecklar och tillverkar produkter i polymera material som plast, silikon och TPE till ledande kunder inom medicinteknik, läkemedel, konsumentelektronik, telekom, fordon och andra utvalda industrisektorer.”

Annual report 2024A · The company itself

“Nolatos operativa verksamhet bedrivs inom två kundnära affärsområden: Medical Solutions: Utveckling och tillverkning av komplexa produktsystem och komponenter för medicinteknik, läkemedelsindustri samt diagnostik .”

Annual report 2024A · The company itself

“Ökad global efterfrågan på auto injektorer för Nolato Självadministrerande injektionssystems framgång – ökar patienternas självständighet Autoinjektorer blir allt mer populära inom läkemedelsindustrin för att förenkla egenbehandling av läkemedel. De möjliggör säker och enkel administrering av medicin i hemmet, särskilt vid kroniska sjukdomar som diabetes, multipel skleros (MS), hormonbehandling och viktminskning, vilket minskar behovet av sjukhusbesök och frigör vårdresurser. Den växande efterfrågan drivs av tekniska framsteg, en åldrande befolkning, och en ökad acceptans för självmedicinering efter pandemin.”

Annual report 2024A · The company itself

“Genom unik kompetens inom tillverkning och utveckling av polymera produkter för ledande företag inom utvalda branscher, kan koncernen med hjälp av avancerad teknologi skapa hållbara och kostnadseffektiva lösningar för kundanpassade produkter.”

Annual report 2024A · The company itself

“Medical Solutions omsättning uppgick till 5.434 MSEK (5.308), justerat för valuta och förvärv ökade omsättningen med 2 procent.”

Annual report 2024A · The company itself

“Vi använder den för att producera kirurgiinstrument och katetrar samt EMC-packningar med mera.”

Annual report 2024A · The company itself

“The MFS organic sales decrease of 3.1% was driven by a decrease in the medical contract manufacturing business product line that was divested in the fourth quarter of 2025. MFS organic sales were up 1.0% year over year excluding the decrease in the medical contract manufacturing product line.”

Annual report 2025A · The company itself

“Key strategic markets include beverage containers and food cans, electric batteries, appliances, automotive, building and construction, composites, electronics and medical. •Nonwovens – Dispensing, coating, and laminating systems for applying adhesives, lotions, liquids, and fibers to disposable products and continuous roll goods. Key strategic markets include adult incontinence products, baby diapers and child-training pants, hygiene products and surgical drapes, gowns, shoe covers and face masks. •Packaging – Automated adhesive dispensing systems used in the rigid packaged goods industries.”

Annual report 2025A · The company itself

“This segment includes components and device solutions for medical, life science, high-tech industrial, and other diverse end markets. •Engineered Fluid Solutions – Precision manual and semi-automated dispensers and highly engineered single-use plastic molded syringes, cartridges, tips and fluid connection components. Products are used within critical medical and industrial production processes and for applying and controlling the flow of adhesives, sealants, and lubricants.”

Annual report 2025A · The company itself

“Key strategic markets include electronics, industrial, medical, and animal health. •Medical Interventional Solutions – Interventional solutions for minimally invasive interventional surgical procedures, including engineered shafts and interventional delivery systems, medical tubing, balloons, balloon inflators, nitinol devices, cardiovascular cannula and biomaterial delivery. Key strategic markets include cardiovascular, structural heart, neurovascular and gastroenterology. •Medical Fluid Components – Proprietary single-use plastic components in medical applications, including drug delivery and needle-free infusion valves, single-use fluid transfer components, and other related components.”

Annual report 2025A · The company itself

“Key strategic end markets include drug infusion, IV & drug delivery, patient care, surgical and biopharma.”

Annual report 2025A · The company itself

“Kunderna är verksamma inom segmenten Industrial, Communication, Medtech och Greentech.”

Annual report 2024A · The company itself

“NOTE delar in sin försäljning i fyra kundsegment. En beskrivning av dessa finns under Detta är NOTE, på sidan 2.”

Annual report 2024A · The company itself

“Minute impurities in our manufacturing materials, contaminants in the manufacturing environment, manufacturing equipment failures, and other defects can cause our products to be non-compliant with customer requirements or otherwise nonfunctional. We face exposure to warranty and product liability claims if our products fail to perform as expected or their failure results, or is alleged to result, in bodily injury or property damage (or both).”

Annual report 2025A · The company itself

“Under året fortsatte utvecklingen av OX640, ett nasalt adrenalinläkemedel för anafylaxi. Behandlingen testades framgångsrikt i försökspersoner med allergisk rinit, vilket är en vanlig reaktion vid anafylaxi. I årtionden har standardbehandlingen varit administrering av adrenalin genom auto injektorer. Ett nålfritt alternativ som dessutom är lättare att bära med sig och har längre hållbarhet har potential att revolutionera marknaden och nå ut till fler patienter.”

Annual report 2024A · The company itself

“Orion has developed an understanding of how particularly vulnerable end-user populations, or end-users using particular products may be at greater risk of harm, through conducting a careful analysis and assessment, which is based on pharmaceutical industry ethical and legal requirements in the EU and globally. All of the material risks and opportunities are related to all end-users pharmaceutical products.”

Annual report 2025A · The company itself

“The Group’s objectives for 2026 are centred on three priorities: • Continue to develop Reponex’ key programs towards valueinflection points that support future licensing and partnership agreements • Identify and assess additional acquisition opportunities aligned with PEG’s updated investment strategy across Pharma and Medical Devices (including MedTech) • Strengthen the Group’s capital preparedness to ensure robust execution of the strategy and support portfolio development In executing these priorities, the Group will continue to maintain a lean cost base and a high degree of cost flexibility, supporting capital efficiency while ensuring continued progression of the portfolio and development activities.”

Annual report 2025A · The company itself

“In line with the updated investment strategy, PEG will continue to identify and evaluate acquisition opportunities across Pharma and Medical Devices/MedTech and apply disciplined screening and governance through the Investment Committee.”

Annual report 2025A · The company itself

“Use of Hexvix/Cysview requires installation of Blue Light Cystoscopes which are manufactured and sold by other companies, only one of which is approved with Cysview in the U.S. These companies’ ability and willingness to develop and promote these products may affect Photocure’s results and cash flows.”

Annual report 2024A · The company itself

“New clinical research and real world data provide the scientific community with new insights to improve bladder cancer care. In 2024, we have engaged in 15 research projects, underscoring our commitment and tangible contribution to the lives of bladder cancer patients through our support of the scientific advancement of care in this domain.”

Annual report 2024A · The company itself

“Photocure’s product Hexvix ® /Cysview ® is available in over 30 countries, with its established specialist commercial and medical teams in North America and Europe.”

Annual report 2024A · The company itself

“För Viobac AS har vi utvecklat en avancerad medicinteknisk produkt som med UV-ljus reducerar bakterietillväxt i urinkatetrar – en lösning som kan minska sjukhusinfektioner, sänka kostnader och rädda liv.”

Annual report 2024A · The company itself

“Vi i bland annat hållbarhet, digitalisering och automati- Vårt fokus inkluderar bioteknik, medicinteknik och Produktutveckling integrerar avancerad elektronik, design, förser den globala markmjukvara och hållbarhetsaspekter. Prevas erbjuder teknisk expertis och affärs- Nordens försvarsindustri Energibranschen har en avgörande roll för att Norden dustrin påverkas av flera Fordons- och transportin- För Prevas är det viktigt att vara med och fortsätta utveckla framtidens Prevas har lång erfarenhet av konsulttjänster inom mobila nät och bidrar med viktig expertis inom radionära funktioner.”

Annual report 2024A · The company itself

“för den rumänska marknaden och ett med Amico Group som Q-linea utvecklar innovativa lösningar för förbättrad diagnostik av infektionssjukdomar genom tillverkning av instrument och förbrukningsvaror som gynnar patienter, vårdgivare och samhället. Q-lineas lösningar gör det möjligt för vårdgivare att diagnostisera och behandla infektionssjukdomar på kortast möjliga tid. Företagets ledande produkt, ASTar, är ett helautomatiskt instrument för snabb resistensbestämning av positiva blodkulturer, vilket ger svar på ca sex timmar.”

Annual report 2024A · The company itself

“Bolaget utvecklar både förbrukningsartiklar samt instrument med tillhörande mjukvara. Den första förbrukningsartikeln som kan användas med ASTar instrumentet på marknaden är riktad mot sepsis (blodförgiftning) och vi har idag en produkt för analys av så kallade gramnegativa bakterier från prover tagna från patienter med misstänkt sepsis godkänd för klinisk användning.”

Annual report 2024A · The company itself

“IAR’s solutions play a critical role in securing and accelerating the development of smart products in sectors such as automotive, industrial automation and medical devices.”

Annual report 2025A · The company itself

“The above is exacerbated by the fact that our products may be used, and perform critical functions, in various high-risk applications, including but not limited to: automobiles, including ADAS/AD functions; cameras and artificial intelligence, including home and enterprise security; home automation, including smoke and noxious gas detectors; medical condition monitoring; location and asset tracking and management, including wearables for child safety and elderly health; robotics, including public safety drones and autonomous municipality vehicles; and XR for treatment of phobias or PTSD, early detection of disorders or special needs, among others.”

Annual report 2025A · The company itself

“For instance, our QUEST AD-Detect® test portfolio for assessing Alzheimer’s disease risk uses blood specimens, as opposed to testing by more costly or invasive methods, such as testing of cerebral spinal fluid by lumbar puncture.”

Annual report 2025A · The company itself

“The FDA has regulatory responsibility over, among other areas, instruments, software, test systems, collection kits, reagents and other devices used by clinical laboratories to perform diagnostic testing in the United States. The FDA also regulates drugs-of-abuse testing for employers and insurers, testing for blood bank purposes and testing of donors of human cells for purposes such as in vitro fertilization. We offer companion and complementary diagnostic tests to pharmaceutical companies that are regulated by the FDA.”

Annual report 2025A · The company itself

“RAYSEARCHS KONKURRENTER Allt sedan RaySearch lanserade sitt eget dosplaneringssystem 2012 har man aktivt arbetat med att övertyga kliniker om vikten av att ta oberoende beslut vad gäller mjukvara respektive strålbehandlingsmaskin. Denna strategi har i många fall varit lyckosam, framför allt hos kliniker med avancerade behandlingar eller kliniker i behov av effektivisering.”

Annual report 2024A · The company itself

“RaySearch och Varian har ett interoperabilitetsavtal som gör det möjligt att koppla RayCare till Varians linjäraccelerator TrueBeam®. I september 2024 behandlades den första patienten på en klinik med kombinationen TrueBeam, RayCare och RayStation.”

Annual report 2024A · The company itself

“IBA (BELGIEN), som är världsledande inom lösningar för protonbehandling, inledde 2016 ett långsiktigt, strategiskt samarbete med RaySearch. Sedan dess har RaySearch anpassat RayStation och RayCare till IBA:s produkter för att kunna erbjuda en helhetslösning för mjukvara och hårdvara.”

Annual report 2024A · The company itself

“ACCURAY (USA) och RaySearch har ett långsiktigt samarbetsavtal om att utveckla och marknadsföra helt integrerade lösningar som kombinerar RayStation och RayCare med behandlingssystemen Radixact® och CyberKnife®.”

Annual report 2024A · The company itself

“TILLVERKARE AV YTSKANNINGSSYSTEM Ytskanningsteknologi används för SGRT (Surface Guided Radiation Therapy) inom strålbehandling, bland annat för patientpositionering och övervakning av patientrörelser. VISION RT är en global leverantör inom SGRT.”

Annual report 2024A · The company itself

“I SIFFROR Nyckeltal OM RAYSEARCH RaySearch Laboratories AB (publ) är ett medicintekniskt företag som utvecklar innovativa mjukvarulösningar för förbättrad cancerbehandling. Företaget utvecklar och marknadsför dosplaneringssystemet RayStation®* och onkologiinformationssystemet RayCare®* till kliniker över hela världen och distribuerar produkter via licensavtal med ledande medicinteknikföretag.”

Annual report 2024A · The company itself

“Under året lanserades en ny modul för bildstyrd leverablation i RayStation. Detta innebär att RaySearch nu tar ett steg utanför strålbehandlingsområdet.”

Annual report 2024A · The company itself

“I början av 2024 förvärvade vi produkten DrugLog av Pharmacolog i Uppsala för att komplettera vårt erbjudande och ta ytterligare steg mot att tillhandahålla mjukvarustöd för alla typer av cancerbehandlingar, inklusive kemoterapi och kirurgi.”

Annual report 2024A · The company itself

“RaySearch erbjuder innovativa mjukvarulösningar för att förbättra effektivitet och behandlingsresultat för cancervården genom fem produkter: Dosplaneringssystemet RayStation, onkologiinformationssystemet RayCare, analyssystemet RayIntelligence, behandlingsstyrsystemet RayCommand och den nya produkten DrugLog, som minskar risken för fel vid beredning av läkemedel.”

Annual report 2024A · The company itself

“Under 2024 såldes RayStation till 94 nya cancerkliniker.”

Annual report 2024A · The company itself

“De har valt att fokusera på utveckling av behandlingssystem som de säljer tillsammans med dosplaneringssystem och onkologiinformationssystem från tredje part, framför allt från RaySearch. Vårt nära samarbete kring både innovation och försäljning har gett båda bolagen stora framgångar inom protonbehandling, där vi tillsammans har en stor marknadsandel.”

Annual report 2024A · The company itself

“Detta innebär att RaySearch nu tar ett steg utanför strålbehandlingsområdet. Leverablation är en behandlingsmetod där en nål förs in i tumören, varefter tumören förstörs genom värme genererad av mikrovågor eller högfrekventa radiovågor.”

Annual report 2024A · The company itself

“The geographic markets for our products, which encompass Sleep and Breathing Health products and Residential Care Software offerings, are highly competitive and are characterized by frequent product improvements and evolving technology, and new therapies, including existing and new pharmaceuticals. Our ability to compete successfully depends, in part, on our ability to develop, manufacture and sell innovative new products and to enhance existing products that treat OSA more effectively than competing treatments.”

Annual report 2026A · The company itself

“Since the development of continuous positive airway pressure therapy, we have expanded our business by developing or acquiring a number of innovative products and solutions for a broad range of sleep and related breathing health disorders including technologies to be applied in medical and consumer products, life support and ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, and dental devices.”

Annual report 2026A · The company itself

“We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry, or Sleep and Breathing Health, and the supply of business management software as a service to residential healthcare providers, or Residential Care Software.”

Annual report 2026A · The company itself

“Sleep and Breathing Health Net revenue from our Sleep and Breathing Health business for the year ended June 30, 2026 increased to $4,978 million from $4,505 million for the year ended June 30, 2025, an increase of $473 million or 10%.”

Annual report 2026A · The company itself

“Net revenue from devices for the year ended June 30, 2026 increased to $2,892 million from $2,665 million for the year ended June 30, 2025, an increase of $227 million or 9%, including an increase of 7% in the Americas and an increase of 11% in Rest of World (a 6% increase on a constant currency basis).”

Annual report 2026A · The company itself

“Sales of intraocular pressure measuring devices, or tonometers, were good during 2025. In particular, sales of the iCare IC200 tonometer were strong during 2025. iCare HOME2 tonometer performed well. iCare TONOVET Pro and iCare TONOVET Pet for veterinary use performed very strongly during 2025.”

Annual report 2025A · The company itself

“In fundus imaging devices, iCare DRSplus in particular, performed strongly during 2025.”

Annual report 2025A · The company itself

“During the financial year, we started sales of the new iCare MAIA microperimeter and launched the cloud-based iCare ALTIUS eye health information management solution in the United States.”

Annual report 2025A · The company itself

“Sales of the iCare MAIA microperimeter performed well in the final quarter of the year, and the device’s reception in the market has been extremely promising.”

Annual report 2025A · The company itself

“Our Strategy Our strategy is to develop and deliver innovative products, services and solutions in high-growth markets that utilize our knowledge and expertise to address customers’ critical needs and drive scientific breakthroughs.”

Annual report 2025A · The company itself

“Healthcare: Accelerate growth from wireless patient monitoring infrastructure”

Annual report 2025A · The company itself

“Här är några av deras vanligaste frågor under 2024 och våra svar. utbudet är fokuserat på snabbväxande segment, som elfordon och medicinteknik, vilket passar mycket bra in i vår strategi.”

Annual report 2024A · The company itself

“▪ Risk of inadequate oversight and governance of AI in creating learning and media content and digital solutions could lead to IP exposure, regulatory non-compliance, loss of market differentiation reflected in the loss of trust of Sanoma's customers, reputational damage and loss of revenue ▪ The risk that Sanoma mismanages its intellectual property rights (including trademarks, copyrights, and licensing agreements) by failing to protect or enforce its own IP or by infringing third-party rights, resulting in financial losses due to litigation costs, fines, lost royalty income, or loss of sales revenue, or weakened market position Anti- Harassment Standard Aims to ensure a safe and respectful working environment by prohibiting all forms of harassment, including sexual harassment, bullying, and discrimination.”

Annual report 2025A · The company itself

“Scanfil seeks to broaden its customer base and expand its geographical presence through acquisitions, thereby strengthening its position in the strategic Aerospace & Defense and Medtech & Life Science sectors.”

Annual report 2025A · The company itself

“Through acquisitions, Scanfil aims to bring in new customers, strengthen its foothold in strategic growth sectors – Aerospace & Defense and Medtech & Life Science – and expand geographical presence.”

Annual report 2025A · The company itself

“MB Elettronica, acquisition completed in January 2026, enhances Scanfil’s footprint in Southern Europe with a strong portfolio in Aerospace & Defense and Medtech & Life Science customer groups.”

Annual report 2025A · The company itself

“Serving around 160 clients, Scanfil produces approximately 10,000 products annually, ranging from medical devices to heat pumps and recycling systems.”

Annual report 2025A · The company itself

“Medtech & Life Science turnover decreased by 6.7% in the full year. New customer projects won in the full year totaled EUR 40.7 million, an increase of EUR 10.5 million from last year. Medtech & Life Science is one of our strategic growth areas, and we continue investing in sales and capabilities.”

Annual report 2025A · The company itself

“It caters to leading companies in the Industrial, Energy & Cleantech, and Medtech & Life Science sectors.”

Annual report 2025A · The company itself

“Sedana Medical AB (publ) är en pionjär inom medicinteknik och läkemedel med fokus på inhalationssedering för att förbättra patientens liv under och efter sedering. Genom kombinationen av den medicintekniska produkten Sedaconda ACD och läkemedlet Sedaconda (isofluran), tillhandahåller Sedana Medical en effektiv, enkel och förutsägbar metod för inhalations sedering av mekaniskt ventilerade patienter i intensivvård.”

Annual report 2024A · The company itself

“Sedana Medicals erbjudande består av den medicintekniska produkten Sedaconda ACD (Anaesthetic Conserving Device), läkemedlet Sedaconda (isofluran) och tillbehör. Sedaconda ACD, avsedd för engångsbruk och byte var 24:e timme, är en unik och innovativ produkt för enkel och effektiv administrering av inhalationsanestetika som fungerar smidigt i kombination med ventilatorer, sprutpumpar och gasmonitorer som redan finns på plats på IVA.”

Annual report 2024A · The company itself

“Koncernens verksamhet omfattar utveckling, tillverkning och försäljning av medicintekniska produkter och läkemedel samt utveckling av produkter som bygger på eller har synergier med Sedaconda-teknologin för inhalationssedering. Teknologin möjliggör enkel och säker omvandling av flytande vätska till gas (förgasning) och återanvändning (reflektering) av flyktiga anestetika för användning inom anestesi- och intensivvård. Koncernens produktportfölj omfattar i dagsläget Sedaconda ACD med tillbehör samt Sedaconda (isofluran), koncernens läkemedel som bygger på den välkända substansen isofluran.”

Annual report 2024A · The company itself

“Förutom Senzime finns idag ett fåtal bolag som erbjuder EMG-baserad neuromuskulär övervakning. Senzimes TetraGraph är i dagsläget det enda system som erbjuder en komplett produktportfölj för alla typer av patienter, från små barn till vuxna och även för patienter med skör, känslig hud. att andningstuben tas ut för tidigt med risk för allvarliga komplikationer på grund av kvarstående muskelblockad.”

Annual report 2024A · The company itself

“Bolaget har en produktportfölj av lösningar och fokuserar på att kommersialisera TetraGraph-systemet på narkosmarknaden. TetraGraph är en unikt system som säkerställer att patienter får rätt dos av narkosrelaterade läkemedel och indikerar när det är säkert att låta patienter andas på egen hand igen efter operation.”

Annual report 2024A · The company itself

“Försäljningen av engångssensorer mer än fördubblades 2024 och stod för två tredjedelar av all försäljning. Under året levererades 900 TetraGraph-system till ledande sjukhus över hela världen och användningsgraden ökade kontinuerligt.”

Annual report 2024A · The company itself

“Den totala försäljningen av engångssensorer ökade med 101 procent justerat för valutaförändringar.”

Annual report 2024A · The company itself

“Senzime marknadsför två olika patientövervakningssystem; TetraGraph för övervakning av neuromuskulär funktion under operation samt ExSpiron 2Xi för övervakning av andningsvolym typiskt efter operation.”

Annual report 2024A · The company itself

“Although we invest significant resources in the testing of our products, from time to time we become aware of alleged defects in our products after they have been shipped, and we may be required to incur additional development and remediation costs or cash payments to settle claims pursuant to warranty and indemnification provisions in our customer contracts and purchase orders. Certain of our products, including “high reliability” solutions, may not be able to perform under stringent operating conditions. Examples of our “high reliability” solutions include products used in the aerospace, automotive, defense, and medical markets.”

Annual report 2025A · The company itself

“medicinsk screening för sömnapné. Att bredda vårt produkterbjudande är en strategisk satsning som syftar till att stärka både vårt kommersiella erbjudande och vår marknadsposition.”

Annual report 2024A · The company itself

“Nu undersöks också med vilken kvalitet som denna teknik kan användas för att monitorera andningsstörningar och exempelvis identifiera användare som visar tecken på sömnapné, som är ett stort folkhälsproblem.”

Annual report 2024A · The company itself

“While it is not possible to predict the outcome of patent and other intellectual property litigation, such litigation could result in Solventum’s payment of significant monetary damages and/or royalty payments, negatively impact Solventum’s ability to sell current or future products, or prohibit it from enforcing its patent and proprietary rights against others, which could result in a material adverse effect on its business, results of operations, financial condition and cash flows.”

Annual report 2025A · The company itself

“MedSurg (57.9% of 2025 total sales) is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer ("OEM"). These solutions are designed to accelerate healing, prevent complications, and lower the total cost of care. Additionally, our comprehensive range of surgical solutions are designed to mitigate a patient’s risk of infection or complications.”

Annual report 2025A · The company itself

“Dental Solutions (16.2% of 2025 total sales) is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents that span the "life of the tooth," including products designed for preventative dental care, direct and indirect restoration, and broad orthodontic needs.”

Annual report 2025A · The company itself

“Solventum is exposed to risks associated with product liability claims, including existing claims and claims resulting from the actions or inactions of its customers or third parties, and product recalls or safety alerts that are outside of its control. Solventum is exposed to potential product liability risks that are inherent in the design, manufacture and marketing of medical technologies. Customers or their patients have brought and likely will continue to bring product liability claims if Solventum’s products fail, or allegedly fail, to perform as expected or show a failure rate that is higher than expected, or the use of Solventum’s products results, or is alleged to result, in bodily injury, death or property damage.”

Annual report 2025A · The company itself

“Sterile Plastic Vials, i COC og PP.”

Annual report 2025A · The company itself

“SP Meditec er en af Nordens største leverandører af sprøjtestøbte plastkomponenter til medicoindustrien.”

Annual report 2025A · The company itself

“SP Medical fokuserer på udvikling, produktion og distribution af guidewires til bl.a. kardiologi, radiologi og urologi og er blandt de største i Europa.”

Annual report 2025A · The company itself

“MedicoPack udvikler og producerer plastemballage til medicinsk brug inden for injektions- og infusionsterapi og leverer til den globale medico- og healthcareindustri.”

Annual report 2025A · The company itself

“These include: consumable products, such as detergents, endoscopy accessories, barrier products, instruments and tools; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment, such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as operating room (“OR”) integration.”

Annual report 2026A · The company itself

“Our products include pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators.”

Annual report 2026A · The company itself

“BUSINESS INTRODUCTION STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe.”

Annual report 2026A · The company itself

“Our AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization.”

Annual report 2026A · The company itself

“We may be unable to maintain adequate working relationships with healthcare professionals: We work with healthcare professionals in a transparent and responsible manner and seek to maintain these relationships with respected physicians and medical personnel in healthcare organizations, such as hospitals and universities, who assist in product research and development. We rely on these professionals to assist us in the development and improvement of proprietary products.”

Annual report 2025A · The company itself

“Stryker Corporation (Stryker or the Company) is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes.”

Annual report 2025A · The company itself

“Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries. We bring patients and physicians advanced implant designs and specialized instrumentation that make orthopaedic surgery and recovery simpler, faster and more effective.”

Annual report 2025A · The company itself

“KARL THEDÉEN VD OCH KONCERNCHEF Vi investerar för framtida tillväxt Koncernens verksamhet Studsvik levererar tjänster till den internationella kärnkraftsindustrin och till tillverkare av medicinska isotoper.”

Annual report 2024A · The company itself

“Suominen’s nonwovens create value for our customers and end-users by offering safe and high-quality wiping, medical and hygiene products and diverse sustainable alternatives, including biodegradable, compostable and plastic-free products and products manufactured using recycled materials.”

Annual report 2025A · The company itself

“Micron-sized powders are used for applications such as 3D print- ing in the aerospace, medical and consumer elec- tronics sectors.”

Annual report 2024A · The company itself

“Tele2s negativa påverkan på konsumenters hälsa kan uppstå genom defekta produkter, såsom överhettade laddare eller kemikalieläckage som bryter mot RoHS- och REACH-standarder. Dessa problem kan leda till fysiska skador, giftig exponering och förtroendeförlust för Tele2s säkerhetsåtaganden.”

Annual report 2024A · The company itself

“As a manufacturer and distributor of a wide variety of products, including monitoring instruments, gas and flame detection instruments, products used in offshore oil and gas production, products used in transportation and commercial aviation, products used in maritime navigation and products used in medical devices (including X-ray detectors), our results of operations are susceptible to adverse publicity regarding the quality or safety of our products.”

Annual report 2025A · The company itself

“Overview Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.”

Annual report 2025A · The company itself

“Det underlättar för perso - ner med funktionsnedsättningar att interagera med sin utrustning och möjliggör säkrare bilar som kan känna av om föraren är trött.Tekniken förbättrar också användarupplevelsen av persondatorer samt VR- och AR-headset genom att skapa mer engagerande upplevelser inom nästa generations extended reality.”

Annual report 2024A · The company itself

“Partnerskap med NovaSight för CureSight Tobiis eyetracking-teknologi används i Nova- Sights CureSight-behandling av amblyopi hos barn, ett innovativt och bekvämt alternativ till ögonlapp.”

Annual report 2024A · The company itself

“Strategiska samarbeten och design wins inom konsumentelektronik, fordonsindustrin och medicinsk teknologi stärker vår marknadsledande position och ökar kundernas förtroende. Innovationerna möjliggör transformativa tillämpningar som skapar värde för individer, organisationer och samhället.”

Annual report 2024A · The company itself

“Innovationer inom sjuk- och hälsovård Tobii utvidgar användningen av eyetracking inom medicinsk diagnostik och terapeutiska lösningar samt stärker samarbetet med vårdgivare och forskare.”

Annual report 2024A · The company itself

“Våra teknologier driver digital utveckling inom beteendeforskning, fordonssäkerhet, hälsovård, hjälpmedelsteknik, gaming och extended reality. De integreras i enheter som XR-headset, persondatorer, gamingtillbehör, smarta glasögon, medicinsk utrustning och fordon.”

Annual report 2024A · The company itself

“Produkter i miljöer med förhöjd risknivå Översyn av produkter och lösningar Riskutvärderingar, men också utbildningar och workshops, genomförs för att identifiera produkter och kontrakt där det är extra viktigt att produkterna håller för de kvalitets- och funktionskrav som krävs i extremt krävande miljöer, exempelvis inom marin infrastruktur, marina slangar för olja & gas, hälsovård & medicinteknik samt flyg.”

Annual report 2024A · The company itself

“Ett naturligt steg i linje med denna strategi var att etablera det nya affärsområdet Trelleborg Medical Solutions, med fokus på life science och industrins unika kundbehov. Den underliggande marknaden drivs i stor utsträckning av en snabbt växande och åldrande befolkning i många delar av världen. Under året genomförde Trelleborg sitt hittills största förvärv inom medicinteknik. Med förvärvet av Baron Group blir det nya affärsområdet en global ledare inom medicintekniska lösningar baserade på flytande silikon.”

Annual report 2024A · The company itself

“Vuolukivi on esimerkiksi hyväksytysti testattu elintarvikekontaktimateriaali.”

Annual report 2025A · The company itself

“Combines data and analytics expertise with comprehensive technologies and health care knowledge to help life sciences companies, including those in pharmaceuticals and medical technology, adopt a more comprehensive approach to advancing therapeutic discoveries and improving clinical outcomes.”

Annual report 2025A · The company itself

“The technology used in medical equipment and related devices is constantly evolving and, as a result, manufacturers and distributors continue to offer new and upgraded products to health care providers. To compete effectively, we must continually assess our equipment needs and upgrade when significant technological advances occur.”

Annual report 2025A · The company itself

“•In 2025, we recorded $115.8 million of CASGEVY product revenues. This reflects 64 patients receiving infusions of CASGEVY in 2025, including 30 people infused in the fourth quarter.”

Annual report 2025A · The company itself

“Outside of CF, we continue to advance the commercialization of CASGEVY for the treatment of SCD and TDT, and JOURNAVX for the treatment of acute pain.”

Annual report 2025A · The company itself

“In 2025, “Other product revenues” included $115.8 million from CASGEVY and $59.6 million from JOURNAVX.”

Annual report 2025A · The company itself

“Vitrolife Group är en internationell koncern för medicintekniska produkter och genetiska tester inom reproduktion.”

Annual report 2024A · The company itself

“Företaget utvecklar, tillverkar och distribuerar medicintekniska produkter och erbjuder genetiska tester inom reproduktion till IVF-kliniker och deras patienter.”

Annual report 2024A · The company itself

“Beneli är en innovativ kontraktstillverkare som erbjuder tryckt elektronik samt komplexa självhäftande applikationer med höga kvalitetskrav. Kunderna finns främst inom medicinteknikoch fordonsindustrin.”

Annual report 2024A · The company itself

“, en ranibizumab biosimilar (originalläkemedlet är Lucentis ® ) som används i behandling av olika ögonsjukdomar, främst den våta formen av åldersrelaterad makuladegeneration.”

Annual report 2024A · The company itself

“Products Our products include orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT products; bone cement; surgical products; and a suite of integrated digital and robotic technologies.”

Annual report 2025A · The company itself

“Our S.E.T. product category includes sports medicine, biologics, foot and ankle, upper extremities, trauma and CMFT products.”

Annual report 2025A · The company itself

“Additionally, our customers’ needs often vary 13 depending on their sites of care, such as hospitals, hospital systems, ambulatory surgical centers and doctors’ offices, and certain of our competitors have better capabilities to serve certain sites of care than we do. We also face competition from pharmaceutical and other therapies that may be more attractive than, or have other benefits over, our products, or that could affect the frequency, progressions or symptoms of diseases and conditions that our products treat.”

Annual report 2025A · The company itself

“Operational revenue growth was $188 million, or 5%, reflecting growth of $145 million in companion animal products and $43 million in livestock products. •Companion animal operational revenue growth was driven primarily by increased sales of our Simparica franchise products, key dermatology products and our mAb products for OA pain, Librela and Solensia. Table of Contents •Livestock operational revenue growth was due to increased sales in our cattle and fish products, partially offset by lower sales of poultry products.”

Annual report 2025A · The company itself